17-(dimethylaminoethylamino)-17-demethoxygeldanamycin profile

17-(dimethylaminoethylamino)-17-demethoxygeldanamycin, also known as **17-DMAG**, is a synthetic analog of the natural product **geldanamycin**. It is a potent inhibitor of the **heat shock protein 90 (Hsp90)**, a molecular chaperone that plays a critical role in the folding and stability of many proteins involved in cell signaling and survival.

**Why is 17-DMAG important for research?**

* **Cancer research:** Hsp90 is overexpressed in many cancer cells and is essential for their survival. 17-DMAG has shown promising preclinical activity against a variety of cancers, including leukemia, lymphoma, breast cancer, and prostate cancer. It works by inhibiting Hsp90, leading to the degradation of client proteins that are essential for cancer cell growth and survival.
* **Mechanism of action:** 17-DMAG serves as a valuable tool for understanding the role of Hsp90 in various cellular processes. By studying its effects on different cell types, researchers can gain insights into the mechanisms underlying its anticancer activity and potential off-target effects.
* **Drug development:** 17-DMAG has been investigated in clinical trials as a potential anticancer drug. While it has shown some efficacy, further research is needed to optimize its therapeutic potential and address potential side effects.

**Key features of 17-DMAG:**

* **Potent Hsp90 inhibitor:** It binds tightly to Hsp90, blocking its chaperone activity and leading to the degradation of its client proteins.
* **Synthetic analog:** It is a synthetic derivative of geldanamycin, designed to improve its pharmacological properties, such as bioavailability and toxicity.
* **Preclinical efficacy:** It has demonstrated significant anti-cancer activity in preclinical studies.
* **Clinical trials:** It has been evaluated in clinical trials for various cancers, but further research is needed to optimize its therapeutic potential.

**Overall, 17-DMAG is an important research tool that has the potential to lead to new cancer therapies. Its ability to target Hsp90 makes it a valuable agent for studying cancer cell survival and developing new anticancer drugs.**

17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

alvespimycin : A 19-membered macrocyle that is geldanamycin in which the methoxy group attached to the benzoquinone moiety has been replaced by a 2-(N,N-dimethylamino)ethylamino group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	5288674
CHEBI ID	65324
CHEBI ID	94772
SCHEMBL ID	5449716
MeSH ID	M0479533

Synonym
HY-10389
(4e,6z,10e,12s,13r,16r)-19-(2-(dimethylamino)ethylamino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate
17-desmethoxy-17-n,n-dimethylaminoethylamino-geldanamycin
nsc707545
nsc-707545
nsc 707545
kos 1022
17-(dimethylaminoethylamino)-17-demethoxy-geldanamycin
17-dimethylaminoethylamino-17-demethoxy-geldanamycin
alvespimycin
((4e,6z,8s,9s,10e,12s,13r,14s,16r)-19-(2-dimethylaminoethylamino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo(16.3.1)docosa-4,6,10,18,21-pentaen-9-yl) carbamate
kos1022
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
chebi:65324 ,
dmag
467214-20-6
alvespimycin [inn]
001l2fe0m3 ,
unii-001l2fe0m3
17-dimethylaminoethylamino-17-demethoxygeldanamycin
CS-0912
(4e,6z,8s,9s,10e,12s,13r,14s,16r)-19-{[2-(dimethylamino)ethyl]amino}-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate
150270-08-9
alvespimycin [who-dd]
geldanamycin, 17-demethoxy-17-((2-(dimethylamino)ethyl)amino)-
(4e,6z,8s,9s,10e,12s,13r,14s,16r)-19-((2-(dimethylamino)ethyl)amino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo(16.3.1)docosa-1(21),4,6,10,18-pentaen-9-yl carbamate
BRD-K83988098-003-01-8
M03709
SCHEMBL5449716
bdbm50005781
AC-33174
EX-A1103
17-demethoxy-17-[[2-(dimethylamino)ethyl]amino]geldanamycin
CHEBI:94772
gtpl9828
[(3r,5s,6r,7s,8e,10s,11s,12z,14e)-21-[2-(dimethylamino)ethylamino]-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate
DB12442
Q4552287
KUFRQPKVAWMTJO-LMZWQJSESA-N
BRD-K83988098-001-02-0
DTXSID00963646
[(4e,6z,8s,9s,10e,12s,13r,14s,16r)-19-[2-(dimethylamino)ethylamino]-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin hcl
A1-50459
dimethylaminoethylamino-17-demethoxygeldanamycin, 17-

Excerpt	Reference	Relevance
" All adverse effects were fully reversible in surviving animals after treatment was complete."	( Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance. Brown, AP; Covey, JM; Egorin, MJ; Eiseman, JL; Glaze, ER; Holleran, JL; Johnson, WD; Lambert, AL; Levine, BS; McCormick, DL; Page, JG; Sausville, EA; Smith, AC; Tomaszewski, JE, 2005)	0.59
" In this study, we tested the hypothesis that the low lysosomal pH of normal cells plays an important role in protecting normal tissues from the toxic effects of lysosomotropic anticancer drugs."	( The role of lysosomes in limiting drug toxicity in mice. Forrest, ML; Krise, JP; Ndolo, RA, 2010)	0.36
" Because of its adverse effects on liver, its less toxic derivatives 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) and 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) are currently being evaluated for the treatment of cancer."	( Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs. Goldstein, S; Hyodo, F; Ishii, H; Krishna, MC; Mitchell, JB; Samuni, U; Samuni, Y, 2010)	0.57
" 17-DMAG has the possibility to be a safe and effective anti-ototoxic drug."	( 17-DMAG induces Hsp70 and protects the auditory hair cells from kanamycin ototoxicity in vitro. Bing, D; Chen, J; Chen, Q; Chu, H; Cui, Y; Liu, Y; Pan, C; Sun, Y; Wang, S; Yu, Y; Zhou, L, 2015)	0.42

Excerpt	Reference	Relevance
" The pharmacokinetic and metabolite data generated should prove relevant to the design of additional preclinical studies as well as to contemplated clinical trials of 17DMAG and could be useful in their interpretation."	( Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Covey, JM; Egorin, MJ; Eiseman, JL; Hamburger, DR; Lagattuta, TF; Musser, SM; White, KD, 2002)	0.56
"We have used a semimechanistic pharmacodynamic model to characterize concentration-effect relationships of ATO and HSP90 inhibitors on constitutive STAT3 activity, HSP70 expression, and cell death in a cell line model."	( Synergism between arsenic trioxide and heat shock protein 90 inhibitors on signal transducer and activator of transcription protein 3 activity--pharmacodynamic drug-drug interaction modeling. Brady, MT; Earp, JC; Jusko, WJ; Keng, MK; Wetzler, M, 2007)	0.34
" Hsp70 induction in tumor and liver tissue was used as a pharmacodynamic measure of Hsp90 inhibition and stress response induction."	( Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Carol, H; Houghton, PJ; Keir, ST; Kolb, EA; Lock, R; Maris, JM; Morton, CL; Phelps, DA; Reynolds, CP; Smith, MA; Wu, J, 2008)	0.35
" 17DMAG half-life was 24 +/- 15 hours."	( Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. Belani, CP; Egorin, MJ; Erlichman, C; Holleran, JL; Ivy, SP; Naret, C; Ramalingam, SS; Ramanathan, RK; Remick, SC; TenEyck, CJ, 2010)	0.36
"To identify sources of exposure variability for the tumor growth inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) using a population pharmacokinetic analysis."	( Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors. Aregbe, AO; Belani, CP; Bies, RR; Egorin, MJ; Ivy, PS; Ramalingam, S; Ramanathan, RK; Scher, HI; Sherer, EA; Solit, DB, 2012)	0.38
" Population pharmacokinetic analysis of the 17-DMAG plasma concentration with time was performed using nonlinear mixed effect modeling to evaluate the effects of covariates, inter-individual variability, and between-occasion variability on model parameters using a stepwise forward addition then backward elimination modeling approach."	( Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors. Aregbe, AO; Belani, CP; Bies, RR; Egorin, MJ; Ivy, PS; Ramalingam, S; Ramanathan, RK; Scher, HI; Sherer, EA; Solit, DB, 2012)	0.38
"Population pharmacokinetic analysis of 17-DMAG found no significant covariate effects and considerable inter-individual variability; this implies a wide range of exposures in the population and which may affect treatment outcome."	( Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors. Aregbe, AO; Belani, CP; Bies, RR; Egorin, MJ; Ivy, PS; Ramalingam, S; Ramanathan, RK; Scher, HI; Sherer, EA; Solit, DB, 2012)	0.38
" Pharmacokinetic models of alvespimycin would help in the understanding of drug disposition, predicting drug exposure and interpreting dose-response relationship."	( A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans. Hu, ZY; Lu, J; Zhao, Y, 2014)	0.4
"A literature search was performed to collect pharmacokinetic data for alvespimycin."	( A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans. Hu, ZY; Lu, J; Zhao, Y, 2014)	0.4

Excerpt	Reference	Relevance
" The oral bioavailability of 17-DMAG might be of advantage in investigating the potential of this compound in clinical trials with antiangiogenic as well as antiproliferative endpoints."	( Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Belotti, D; Borsotti, P; Burger, AM; Fisher-Nielson, K; Giavazzi, R; Hollingshead, M; Kaur, G; Riccardi, E; Sausville, EA; Thillainathan, J, 2004)	0.61
" Therefore, we have investigated the effects of the orally bioavailable Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) on the radiosensitivity of human tumor cells in vitro and grown as tumor xenografts."	( Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin. Brady, KJ; Bull, EE; Burgan, WE; Camphausen, K; Carter, DJ; Cerra, MA; Dote, H; Hollingshead, MG; Oswald, KA; Tofilon, PJ, 2004)	0.76
" Evidence of oral bioavailability of 17-DMAG in a saline-based formulation prompted more detailed examination of its antitumor efficacy in vivo."	( In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Alley, M; Borgel, S; Burger, AM; Fiebig, HH; Hollingshead, M; Pacula-Cox, C; Sausville, EA, 2005)	0.33
" Hsp90 inhibitors which are derivates of the natural compound geldanamycin, such as the orally bioavailable 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), are currently being tested in clinical trials and small molecule inhibitors are in development."	( Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo. Cao, MP; Hedley, DW; Pham, NA; Schwock, J, 2008)	0.56
" Optimization of a screening hit using structure-based design and modification of log D and chemical structural features led to the identification of a class of orally bioavailable non-quinone-containing Hsp90 inhibitors."	( Dihydroxyphenylisoindoline amides as orally bioavailable inhibitors of the heat shock protein 90 (hsp90) molecular chaperone. Davies, JF; Digits, JA; Elleraas, J; Gajiwala, KS; Gehring, MR; Hickey, MJ; Huang, B; Kung, PP; Mehta, P; Neul, D; Rodgers, C; Skaptason, J; Wang, J; Yamazaki, S; Yin, MJ; Zhang, G; Zhou, JZ; Zientek, M, 2010)	0.36

Excerpt	Relevance	Reference
" In summary, these results suggest that dosage will be a critical factor in the treatment of tumor patients with HSP90 inhibitors."	( Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors. Franke, C; Hahn, T; Ibrahim, NO; Katschinski, DM; Stiehl, DP; Wenger, RH; Wirthner, R, 2005)	0.33
" Furthermore, efficacy experiments performed in a NCI-N87 mouse xenograft model demonstrated tumor regression in some dosing regimens."	( Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90. Aay, N; Anand, NK; Arcalas, A; Baik, T; Blazey, CM; Bowles, OJ; Buhr, CA; Bussenius, J; Costanzo, S; Curtis, JK; DeFina, SC; Dubenko, L; Heuer, TS; Huang, P; Jaeger, C; Joshi, A; Kennedy, AR; Kim, AI; Lara, K; Lee, J; Li, J; Lougheed, JC; Ma, S; Malek, S; Manalo, JC; Martini, JF; McGrath, G; Nicoll, M; Nuss, JM; Pack, M; Peto, CJ; Rice, KD; Tsang, TH; Wang, L; Womble, SW; Yakes, M; Zhang, W, 2012)	0.38
" Pharmacokinetic models of alvespimycin would help in the understanding of drug disposition, predicting drug exposure and interpreting dose-response relationship."	( A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans. Hu, ZY; Lu, J; Zhao, Y, 2014)	0.4
" A refined PBPK model would benefit the understanding of dose-response relationships and optimization of dosing regimens."	( A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans. Hu, ZY; Lu, J; Zhao, Y, 2014)	0.4
" Based on the dose-response study, synergistic interactions between the two regimens were evaluated using clonogenic assay and combination index values."	( Synergistic Antitumor Effects of Combined Treatment with HSP90 Inhibitor and PI3K/mTOR Dual Inhibitor in Cisplatin-Resistant Human Bladder Cancer Cells. Cho, NH; Choi, YD; Gong, MK; Kang, J; Kim, HJ; Rha, SY; Yoon, CY; Yun, M, 2020)	0.56

Role	Description
Hsp90 inhibitor	An EC 3.6.4.10 (non-chaperonin molecular chaperone ATPase) inhibitor that blocks the action of heat shock protein 90.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
secondary amino compound	A compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
tertiary amino compound	A compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
ansamycin	A class of macrocyclic lactams that consist of an aromatic (phenyl or naphthyl) or quinonoid (benzoquinone or naphthoquinone) moiety that is bridged by an aliphatic chain.
1,4-benzoquinones	Any member of the class of benzoquinones that is 1,4-benzoquinone or its C-substituted derivatives.
carbamate ester	Any ester of carbamic acid or its N-substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Lysine-specific demethylase 6B	Homo sapiens (human)	IC50 (µMol)	0.4000	0.0160	1.6672	6.9000	AID1885317
Lysine-specific demethylase 4B	Homo sapiens (human)	IC50 (µMol)	0.7000	0.2000	1.2200	3.8000	AID1885314
Heat shock protein HSP 90-alpha	Homo sapiens (human)	IC50 (µMol)	0.1699	0.0004	0.6950	10.0000	AID1625290; AID1632347; AID344853; AID344854; AID344856; AID444595; AID596787
Heat shock protein HSP 90-alpha	Homo sapiens (human)	Ki	0.6800	0.0002	0.5415	2.7000	AID596788
Heat shock protein HSP 90-beta	Homo sapiens (human)	IC50 (µMol)	0.2724	0.0010	0.6836	10.0000	AID1076813; AID1127396; AID1127397; AID1625290; AID344853; AID344854; AID344856; AID395892; AID444595; AID596787
5-hydroxytryptamine receptor 1A	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0036	0.0003	1.3833	8.4000	AID327961
Lysine-specific demethylase 5A	Homo sapiens (human)	IC50 (µMol)	0.1300	0.1300	2.3747	10.0000	AID1885316
Hypoxia-inducible factor 1-alpha	Homo sapiens (human)	IC50 (µMol)	5.0358	0.0007	2.4652	9.2100	AID291914; AID291915; AID327961; AID422511; AID422513; AID485530
Endothelial PAS domain-containing protein 1	Homo sapiens (human)	IC50 (µMol)	7.5251	0.0030	2.6002	8.5100	AID291914; AID291915; AID327961; AID422513
Lysine-specific demethylase 4C	Homo sapiens (human)	IC50 (µMol)	0.7000	0.1600	2.1148	9.4000	AID1885315
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0460	0.0190	1.7054	7.0000	AID266551
Heat shock protein HSP 90-alpha	Homo sapiens (human)	EC50 (µMol)	0.0236	0.0040	0.1331	1.2000	AID266546; AID266550; AID266551; AID266552; AID266553; AID344858
Heat shock protein HSP 90-alpha	Homo sapiens (human)	Kd	0.3623	0.0003	0.9488	9.8000	AID254267; AID394598; AID394599
Heat shock protein HSP 90-beta	Homo sapiens (human)	EC50 (µMol)	0.0236	0.0040	0.2385	1.7000	AID266546; AID266550; AID266551; AID266552; AID266553; AID344858
Heat shock protein HSP 90-beta	Homo sapiens (human)	Kd	0.5000	0.0003	1.3330	9.8000	AID350568
Cholesteryl ester transfer protein	Homo sapiens (human)	Kd	0.0870	0.0870	0.1235	0.1600	AID394599
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0460	0.0190	1.7054	7.0000	AID266551
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0460	0.0190	1.7054	7.0000	AID266551
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0460	0.0190	1.7367	7.0000	AID266551
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0460	0.0190	1.7054	7.0000	AID266551
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0460	0.0190	1.7054	7.0000	AID266551
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0460	0.0190	1.7054	7.0000	AID266551
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0460	0.0001	1.4693	7.0000	AID266551
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0460	0.0190	1.7054	7.0000	AID266551
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0460	0.0190	1.7054	7.0000	AID266551
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0460	0.0190	1.7054	7.0000	AID266551
Endoplasmin	Canis lupus familiaris (dog)	EC50 (µMol)	0.0650	0.0480	0.0790	0.1240	AID266547
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0460	0.0190	2.1499	10.0000	AID266551
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0460	0.0190	1.7054	7.0000	AID266551
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0460	0.0190	1.7367	7.0000	AID266551
GABA theta subunit	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0460	0.0190	1.7054	7.0000	AID266551
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0460	0.0190	1.7054	7.0000	AID266551
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
inflammatory response to antigenic stimulus	Lysine-specific demethylase 6B	Homo sapiens (human)
chromatin remodeling	Lysine-specific demethylase 6B	Homo sapiens (human)
response to activity	Lysine-specific demethylase 6B	Homo sapiens (human)
hippocampus development	Lysine-specific demethylase 6B	Homo sapiens (human)
cell fate commitment	Lysine-specific demethylase 6B	Homo sapiens (human)
endothelial cell differentiation	Lysine-specific demethylase 6B	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Lysine-specific demethylase 6B	Homo sapiens (human)
mesodermal cell differentiation	Lysine-specific demethylase 6B	Homo sapiens (human)
cardiac muscle cell differentiation	Lysine-specific demethylase 6B	Homo sapiens (human)
response to fungicide	Lysine-specific demethylase 6B	Homo sapiens (human)
cellular response to hydrogen peroxide	Lysine-specific demethylase 6B	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Lysine-specific demethylase 6B	Homo sapiens (human)
heart development	Lysine-specific demethylase 6B	Homo sapiens (human)
regulation of gene expression	Lysine-specific demethylase 6B	Homo sapiens (human)
brain development	Lysine-specific demethylase 4B	Homo sapiens (human)
chromatin remodeling	Lysine-specific demethylase 4B	Homo sapiens (human)
regulation of gene expression	Lysine-specific demethylase 4B	Homo sapiens (human)
telomere maintenance via telomerase	Heat shock protein HSP 90-alpha	Homo sapiens (human)
neuron migration	Heat shock protein HSP 90-alpha	Homo sapiens (human)
positive regulation of protein phosphorylation	Heat shock protein HSP 90-alpha	Homo sapiens (human)
activation of innate immune response	Heat shock protein HSP 90-alpha	Homo sapiens (human)
positive regulation of defense response to virus by host	Heat shock protein HSP 90-alpha	Homo sapiens (human)
skeletal muscle contraction	Heat shock protein HSP 90-alpha	Homo sapiens (human)
mitochondrial transport	Heat shock protein HSP 90-alpha	Homo sapiens (human)
response to unfolded protein	Heat shock protein HSP 90-alpha	Homo sapiens (human)
response to heat	Heat shock protein HSP 90-alpha	Homo sapiens (human)
response to cold	Heat shock protein HSP 90-alpha	Homo sapiens (human)
response to xenobiotic stimulus	Heat shock protein HSP 90-alpha	Homo sapiens (human)
response to salt stress	Heat shock protein HSP 90-alpha	Homo sapiens (human)
positive regulation of lamellipodium assembly	Heat shock protein HSP 90-alpha	Homo sapiens (human)
cardiac muscle cell apoptotic process	Heat shock protein HSP 90-alpha	Homo sapiens (human)
regulation of protein ubiquitination	Heat shock protein HSP 90-alpha	Homo sapiens (human)
positive regulation of protein polymerization	Heat shock protein HSP 90-alpha	Homo sapiens (human)
positive regulation of interferon-beta production	Heat shock protein HSP 90-alpha	Homo sapiens (human)
regulation of protein localization	Heat shock protein HSP 90-alpha	Homo sapiens (human)
protein refolding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
response to cocaine	Heat shock protein HSP 90-alpha	Homo sapiens (human)
positive regulation of protein import into nucleus	Heat shock protein HSP 90-alpha	Homo sapiens (human)
regulation of apoptotic process	Heat shock protein HSP 90-alpha	Homo sapiens (human)
regulation of protein-containing complex assembly	Heat shock protein HSP 90-alpha	Homo sapiens (human)
protein unfolding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
response to estrogen	Heat shock protein HSP 90-alpha	Homo sapiens (human)
protein insertion into mitochondrial outer membrane	Heat shock protein HSP 90-alpha	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	Heat shock protein HSP 90-alpha	Homo sapiens (human)
positive regulation of protein catabolic process	Heat shock protein HSP 90-alpha	Homo sapiens (human)
positive regulation of cell size	Heat shock protein HSP 90-alpha	Homo sapiens (human)
response to antibiotic	Heat shock protein HSP 90-alpha	Homo sapiens (human)
protein stabilization	Heat shock protein HSP 90-alpha	Homo sapiens (human)
chaperone-mediated protein complex assembly	Heat shock protein HSP 90-alpha	Homo sapiens (human)
positive regulation of cardiac muscle contraction	Heat shock protein HSP 90-alpha	Homo sapiens (human)
chaperone-mediated autophagy	Heat shock protein HSP 90-alpha	Homo sapiens (human)
cellular response to virus	Heat shock protein HSP 90-alpha	Homo sapiens (human)
regulation of postsynaptic membrane neurotransmitter receptor levels	Heat shock protein HSP 90-alpha	Homo sapiens (human)
positive regulation of tau-protein kinase activity	Heat shock protein HSP 90-alpha	Homo sapiens (human)
telomerase holoenzyme complex assembly	Heat shock protein HSP 90-alpha	Homo sapiens (human)
cellular response to heat	Heat shock protein HSP 90-alpha	Homo sapiens (human)
protein folding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
telomere maintenance via telomerase	Heat shock protein HSP 90-beta	Homo sapiens (human)
placenta development	Heat shock protein HSP 90-beta	Homo sapiens (human)
response to unfolded protein	Heat shock protein HSP 90-beta	Homo sapiens (human)
virion attachment to host cell	Heat shock protein HSP 90-beta	Homo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathway	Heat shock protein HSP 90-beta	Homo sapiens (human)
regulation of protein ubiquitination	Heat shock protein HSP 90-beta	Homo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic process	Heat shock protein HSP 90-beta	Homo sapiens (human)
positive regulation of phosphoprotein phosphatase activity	Heat shock protein HSP 90-beta	Homo sapiens (human)
regulation of protein localization	Heat shock protein HSP 90-beta	Homo sapiens (human)
negative regulation of apoptotic process	Heat shock protein HSP 90-beta	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	Heat shock protein HSP 90-beta	Homo sapiens (human)
positive regulation of cell differentiation	Heat shock protein HSP 90-beta	Homo sapiens (human)
chaperone-mediated protein complex assembly	Heat shock protein HSP 90-beta	Homo sapiens (human)
regulation of cell cycle	Heat shock protein HSP 90-beta	Homo sapiens (human)
chaperone-mediated protein folding	Heat shock protein HSP 90-beta	Homo sapiens (human)
cellular response to interleukin-4	Heat shock protein HSP 90-beta	Homo sapiens (human)
supramolecular fiber organization	Heat shock protein HSP 90-beta	Homo sapiens (human)
negative regulation of proteasomal protein catabolic process	Heat shock protein HSP 90-beta	Homo sapiens (human)
telomerase holoenzyme complex assembly	Heat shock protein HSP 90-beta	Homo sapiens (human)
positive regulation of protein localization to cell surface	Heat shock protein HSP 90-beta	Homo sapiens (human)
cellular response to heat	Heat shock protein HSP 90-beta	Homo sapiens (human)
protein folding	Heat shock protein HSP 90-beta	Homo sapiens (human)
protein stabilization	Heat shock protein HSP 90-beta	Homo sapiens (human)
triglyceride metabolic process	Cholesteryl ester transfer protein	Homo sapiens (human)
lipid transport	Cholesteryl ester transfer protein	Homo sapiens (human)
cholesterol metabolic process	Cholesteryl ester transfer protein	Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiation	Cholesteryl ester transfer protein	Homo sapiens (human)
regulation of cholesterol efflux	Cholesteryl ester transfer protein	Homo sapiens (human)
phospholipid transport	Cholesteryl ester transfer protein	Homo sapiens (human)
cholesterol transport	Cholesteryl ester transfer protein	Homo sapiens (human)
positive regulation of cholesterol transport	Cholesteryl ester transfer protein	Homo sapiens (human)
triglyceride transport	Cholesteryl ester transfer protein	Homo sapiens (human)
very-low-density lipoprotein particle remodeling	Cholesteryl ester transfer protein	Homo sapiens (human)
low-density lipoprotein particle remodeling	Cholesteryl ester transfer protein	Homo sapiens (human)
high-density lipoprotein particle remodeling	Cholesteryl ester transfer protein	Homo sapiens (human)
cholesterol homeostasis	Cholesteryl ester transfer protein	Homo sapiens (human)
reverse cholesterol transport	Cholesteryl ester transfer protein	Homo sapiens (human)
phosphatidylcholine metabolic process	Cholesteryl ester transfer protein	Homo sapiens (human)
lipid homeostasis	Cholesteryl ester transfer protein	Homo sapiens (human)
phospholipid homeostasis	Cholesteryl ester transfer protein	Homo sapiens (human)
triglyceride homeostasis	Cholesteryl ester transfer protein	Homo sapiens (human)
positive regulation of phospholipid transport	Cholesteryl ester transfer protein	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Lysine-specific demethylase 5A	Homo sapiens (human)
circadian regulation of gene expression	Lysine-specific demethylase 5A	Homo sapiens (human)
positive regulation of DNA-templated transcription	Lysine-specific demethylase 5A	Homo sapiens (human)
regulation of DNA-binding transcription factor activity	Lysine-specific demethylase 5A	Homo sapiens (human)
facultative heterochromatin formation	Lysine-specific demethylase 5A	Homo sapiens (human)
regulation of DNA-templated transcription	Lysine-specific demethylase 5A	Homo sapiens (human)
chromatin remodeling	Lysine-specific demethylase 5A	Homo sapiens (human)
ERAD pathway	Endoplasmin	Canis lupus familiaris (dog)
positive regulation of chemokine-mediated signaling pathway	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
positive regulation of signaling receptor activity	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
response to hypoxia	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
regulation of DNA-templated transcription	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
response to reactive oxygen species	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
angiogenesis	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
response to hypoxia	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
intracellular glucose homeostasis	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
neural crest cell migration	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
epithelial to mesenchymal transition	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
embryonic placenta development	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
B-1 B cell homeostasis	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
positive regulation of endothelial cell proliferation	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
heart looping	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
positive regulation of neuroblast proliferation	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
chondrocyte differentiation	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
glandular epithelial cell maturation	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
connective tissue replacement involved in inflammatory response wound healing	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
outflow tract morphogenesis	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
cardiac ventricle morphogenesis	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
lactate metabolic process	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
regulation of glycolytic process	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
regulation of DNA-templated transcription	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
intracellular iron ion homeostasis	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
signal transduction	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
neuroblast proliferation	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
lactation	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
visual learning	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
response to iron ion	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
regulation of gene expression	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
vascular endothelial growth factor production	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
positive regulation of vascular endothelial growth factor production	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
positive regulation of gene expression	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
negative regulation of gene expression	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
positive regulation of epithelial cell migration	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
response to muscle activity	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
axonal transport of mitochondrion	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
neural fold elevation formation	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
cerebral cortex development	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
bone mineralization	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
negative regulation of bone mineralization	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathway	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
TOR signaling	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
negative regulation of TOR signaling	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
intracellular oxygen homeostasis	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
positive regulation of chemokine production	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
regulation of transforming growth factor beta2 production	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
collagen metabolic process	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
cellular response to oxidative stress	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
embryonic hemopoiesis	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
insulin secretion involved in cellular response to glucose stimulus	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulus	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
hemoglobin biosynthetic process	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
positive regulation of erythrocyte differentiation	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
positive regulation of angiogenesis	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
positive regulation of DNA-templated transcription	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
negative regulation of growth	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
muscle cell cellular homeostasis	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
positive regulation of hormone biosynthetic process	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
digestive tract morphogenesis	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
positive regulation of nitric-oxide synthase activity	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
neuron apoptotic process	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
elastin metabolic process	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
intestinal epithelial cell maturation	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
epithelial cell differentiation involved in mammary gland alveolus development	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
iris morphogenesis	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
retina vasculature development in camera-type eye	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
negative regulation of thymocyte apoptotic process	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
cellular response to interleukin-1	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
cellular response to hypoxia	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
dopaminergic neuron differentiation	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
mesenchymal cell apoptotic process	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
hypoxia-inducible factor-1alpha signaling pathway	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
cellular response to virus	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
positive regulation of cytokine production involved in inflammatory response	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
positive regulation of mitophagy	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
negative regulation of miRNA transcription	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
positive regulation of miRNA transcription	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
regulation of aerobic respiration	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
regulation of protein neddylation	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
negative regulation of mesenchymal cell apoptotic process	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
response to hypoxia	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
angiogenesis	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
embryonic placenta development	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
blood vessel remodeling	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
regulation of heart rate	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
epithelial cell maturation	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
response to oxidative stress	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
mitochondrion organization	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
signal transduction	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
visual perception	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
erythrocyte differentiation	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
lung development	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
norepinephrine metabolic process	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
mRNA transcription by RNA polymerase II	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
surfactant homeostasis	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
myoblast fate commitment	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
multicellular organismal-level iron ion homeostasis	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
cellular response to hypoxia	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
regulation of protein neddylation	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
blastocyst formation	Lysine-specific demethylase 4C	Homo sapiens (human)
positive regulation of cell population proliferation	Lysine-specific demethylase 4C	Homo sapiens (human)
stem cell population maintenance	Lysine-specific demethylase 4C	Homo sapiens (human)
androgen receptor signaling pathway	Lysine-specific demethylase 4C	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Lysine-specific demethylase 4C	Homo sapiens (human)
regulation of androgen receptor signaling pathway	Lysine-specific demethylase 4C	Homo sapiens (human)
regulation of stem cell differentiation	Lysine-specific demethylase 4C	Homo sapiens (human)
regulation of gene expression	Lysine-specific demethylase 4C	Homo sapiens (human)
chromatin remodeling	Lysine-specific demethylase 4C	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein binding	Lysine-specific demethylase 6B	Homo sapiens (human)
beta-catenin binding	Lysine-specific demethylase 6B	Homo sapiens (human)
histone demethylase activity	Lysine-specific demethylase 6B	Homo sapiens (human)
metal ion binding	Lysine-specific demethylase 6B	Homo sapiens (human)
histone H3K27me2/H3K27me3 demethylase activity	Lysine-specific demethylase 6B	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Lysine-specific demethylase 6B	Homo sapiens (human)
chromatin DNA binding	Lysine-specific demethylase 6B	Homo sapiens (human)
histone demethylase activity	Lysine-specific demethylase 4B	Homo sapiens (human)
histone H3K9 demethylase activity	Lysine-specific demethylase 4B	Homo sapiens (human)
metal ion binding	Lysine-specific demethylase 4B	Homo sapiens (human)
histone H3K36 demethylase activity	Lysine-specific demethylase 4B	Homo sapiens (human)
histone H3K9me2/H3K9me3 demethylase activity	Lysine-specific demethylase 4B	Homo sapiens (human)
UTP binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
CTP binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
RNA binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
mRNA binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
protein binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
ATP binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
GTP binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
ATP hydrolysis activity	Heat shock protein HSP 90-alpha	Homo sapiens (human)
sulfonylurea receptor binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
protein phosphatase binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
MHC class II protein complex binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
nitric-oxide synthase regulator activity	Heat shock protein HSP 90-alpha	Homo sapiens (human)
TPR domain binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
ubiquitin protein ligase binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
dATP binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
identical protein binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
protein homodimerization activity	Heat shock protein HSP 90-alpha	Homo sapiens (human)
histone deacetylase binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
transmembrane transporter binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
tau protein binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
GTPase binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
Rho GDP-dissociation inhibitor binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
DNA polymerase binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
scaffold protein binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
disordered domain specific binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
ATP-dependent protein folding chaperone	Heat shock protein HSP 90-alpha	Homo sapiens (human)
protein tyrosine kinase binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
unfolded protein binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
RNA binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
double-stranded RNA binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
protein binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
ATP binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
ATP hydrolysis activity	Heat shock protein HSP 90-beta	Homo sapiens (human)
protein kinase regulator activity	Heat shock protein HSP 90-beta	Homo sapiens (human)
kinase binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
protein kinase binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
MHC class II protein complex binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
nitric-oxide synthase regulator activity	Heat shock protein HSP 90-beta	Homo sapiens (human)
TPR domain binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
heat shock protein binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
ubiquitin protein ligase binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
peptide binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
identical protein binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
protein homodimerization activity	Heat shock protein HSP 90-beta	Homo sapiens (human)
histone deacetylase binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
ATP-dependent protein binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
protein folding chaperone	Heat shock protein HSP 90-beta	Homo sapiens (human)
cadherin binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
protein dimerization activity	Heat shock protein HSP 90-beta	Homo sapiens (human)
tau protein binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
DNA polymerase binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
disordered domain specific binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
ATP-dependent protein folding chaperone	Heat shock protein HSP 90-beta	Homo sapiens (human)
receptor ligand inhibitor activity	Heat shock protein HSP 90-beta	Homo sapiens (human)
histone methyltransferase binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
unfolded protein binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
phospholipid transporter activity	Cholesteryl ester transfer protein	Homo sapiens (human)
lipid binding	Cholesteryl ester transfer protein	Homo sapiens (human)
cholesterol binding	Cholesteryl ester transfer protein	Homo sapiens (human)
triglyceride binding	Cholesteryl ester transfer protein	Homo sapiens (human)
phosphatidylcholine binding	Cholesteryl ester transfer protein	Homo sapiens (human)
cholesterol transfer activity	Cholesteryl ester transfer protein	Homo sapiens (human)
transcription cis-regulatory region binding	Lysine-specific demethylase 5A	Homo sapiens (human)
DNA binding	Lysine-specific demethylase 5A	Homo sapiens (human)
transcription coactivator activity	Lysine-specific demethylase 5A	Homo sapiens (human)
enzyme inhibitor activity	Lysine-specific demethylase 5A	Homo sapiens (human)
protein binding	Lysine-specific demethylase 5A	Homo sapiens (human)
zinc ion binding	Lysine-specific demethylase 5A	Homo sapiens (human)
chromatin DNA binding	Lysine-specific demethylase 5A	Homo sapiens (human)
histone demethylase activity	Lysine-specific demethylase 5A	Homo sapiens (human)
histone H3K4me/H3K4me2/H3K4me3 demethylase activity	Lysine-specific demethylase 5A	Homo sapiens (human)
methylated histone binding	Lysine-specific demethylase 5A	Homo sapiens (human)
histone binding	Lysine-specific demethylase 5A	Homo sapiens (human)
ATP binding	Endoplasmin	Canis lupus familiaris (dog)
ATP hydrolysis activity	Endoplasmin	Canis lupus familiaris (dog)
ATP-dependent protein folding chaperone	Endoplasmin	Canis lupus familiaris (dog)
DNA-binding transcription factor activity, RNA polymerase II-specific	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
sequence-specific DNA binding	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
DNA-binding transcription activator activity	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
DNA-binding transcription repressor activity	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
transcription coactivator binding	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
p53 binding	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
DNA-binding transcription factor activity	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
protein binding	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
nuclear receptor binding	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
enzyme binding	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
protein kinase binding	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
protein domain specific binding	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
ubiquitin protein ligase binding	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
histone deacetylase binding	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
protein heterodimerization activity	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
Hsp90 protein binding	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
E-box binding	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
transcription regulator activator activity	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
sequence-specific DNA binding	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
transcription coactivator binding	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
protein binding	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
protein heterodimerization activity	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
histone H3K9me2/H3K9me3 demethylase activity	Lysine-specific demethylase 4C	Homo sapiens (human)
zinc ion binding	Lysine-specific demethylase 4C	Homo sapiens (human)
enzyme binding	Lysine-specific demethylase 4C	Homo sapiens (human)
nuclear receptor coactivator activity	Lysine-specific demethylase 4C	Homo sapiens (human)
histone demethylase activity	Lysine-specific demethylase 4C	Homo sapiens (human)
histone H3K9 demethylase activity	Lysine-specific demethylase 4C	Homo sapiens (human)
nuclear androgen receptor binding	Lysine-specific demethylase 4C	Homo sapiens (human)
histone H3K36 demethylase activity	Lysine-specific demethylase 4C	Homo sapiens (human)
H3K9me3 modified histone binding	Lysine-specific demethylase 4C	Homo sapiens (human)
histone H3K9me2/H3K9me3 demethylase activity	Lysine-specific demethylase 4C	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Lysine-specific demethylase 6B	Homo sapiens (human)
nucleoplasm	Lysine-specific demethylase 6B	Homo sapiens (human)
MLL3/4 complex	Lysine-specific demethylase 6B	Homo sapiens (human)
nucleoplasm	Lysine-specific demethylase 4B	Homo sapiens (human)
chromatin	Lysine-specific demethylase 4B	Homo sapiens (human)
nucleus	Lysine-specific demethylase 4B	Homo sapiens (human)
extracellular region	Heat shock protein HSP 90-alpha	Homo sapiens (human)
nucleus	Heat shock protein HSP 90-alpha	Homo sapiens (human)
nucleoplasm	Heat shock protein HSP 90-alpha	Homo sapiens (human)
cytoplasm	Heat shock protein HSP 90-alpha	Homo sapiens (human)
mitochondrion	Heat shock protein HSP 90-alpha	Homo sapiens (human)
cytosol	Heat shock protein HSP 90-alpha	Homo sapiens (human)
plasma membrane	Heat shock protein HSP 90-alpha	Homo sapiens (human)
cell surface	Heat shock protein HSP 90-alpha	Homo sapiens (human)
membrane	Heat shock protein HSP 90-alpha	Homo sapiens (human)
basolateral plasma membrane	Heat shock protein HSP 90-alpha	Homo sapiens (human)
apical plasma membrane	Heat shock protein HSP 90-alpha	Homo sapiens (human)
brush border membrane	Heat shock protein HSP 90-alpha	Homo sapiens (human)
secretory granule lumen	Heat shock protein HSP 90-alpha	Homo sapiens (human)
melanosome	Heat shock protein HSP 90-alpha	Homo sapiens (human)
neuronal cell body	Heat shock protein HSP 90-alpha	Homo sapiens (human)
lysosomal lumen	Heat shock protein HSP 90-alpha	Homo sapiens (human)
dendritic growth cone	Heat shock protein HSP 90-alpha	Homo sapiens (human)
axonal growth cone	Heat shock protein HSP 90-alpha	Homo sapiens (human)
perinuclear region of cytoplasm	Heat shock protein HSP 90-alpha	Homo sapiens (human)
collagen-containing extracellular matrix	Heat shock protein HSP 90-alpha	Homo sapiens (human)
extracellular exosome	Heat shock protein HSP 90-alpha	Homo sapiens (human)
endocytic vesicle lumen	Heat shock protein HSP 90-alpha	Homo sapiens (human)
sperm mitochondrial sheath	Heat shock protein HSP 90-alpha	Homo sapiens (human)
sperm plasma membrane	Heat shock protein HSP 90-alpha	Homo sapiens (human)
ficolin-1-rich granule lumen	Heat shock protein HSP 90-alpha	Homo sapiens (human)
protein-containing complex	Heat shock protein HSP 90-alpha	Homo sapiens (human)
plasma membrane	Heat shock protein HSP 90-alpha	Homo sapiens (human)
neuronal cell body	Heat shock protein HSP 90-alpha	Homo sapiens (human)
perinuclear region of cytoplasm	Heat shock protein HSP 90-alpha	Homo sapiens (human)
myelin sheath	Heat shock protein HSP 90-alpha	Homo sapiens (human)
cytosol	Heat shock protein HSP 90-alpha	Homo sapiens (human)
nucleus	Heat shock protein HSP 90-alpha	Homo sapiens (human)
COP9 signalosome	Heat shock protein HSP 90-beta	Homo sapiens (human)
protein folding chaperone complex	Heat shock protein HSP 90-beta	Homo sapiens (human)
extracellular region	Heat shock protein HSP 90-beta	Homo sapiens (human)
nucleus	Heat shock protein HSP 90-beta	Homo sapiens (human)
nucleoplasm	Heat shock protein HSP 90-beta	Homo sapiens (human)
cytoplasm	Heat shock protein HSP 90-beta	Homo sapiens (human)
mitochondrion	Heat shock protein HSP 90-beta	Homo sapiens (human)
cytosol	Heat shock protein HSP 90-beta	Homo sapiens (human)
cell surface	Heat shock protein HSP 90-beta	Homo sapiens (human)
membrane	Heat shock protein HSP 90-beta	Homo sapiens (human)
secretory granule lumen	Heat shock protein HSP 90-beta	Homo sapiens (human)
melanosome	Heat shock protein HSP 90-beta	Homo sapiens (human)
neuronal cell body	Heat shock protein HSP 90-beta	Homo sapiens (human)
dendritic growth cone	Heat shock protein HSP 90-beta	Homo sapiens (human)
axonal growth cone	Heat shock protein HSP 90-beta	Homo sapiens (human)
perinuclear region of cytoplasm	Heat shock protein HSP 90-beta	Homo sapiens (human)
extracellular exosome	Heat shock protein HSP 90-beta	Homo sapiens (human)
dynein axonemal particle	Heat shock protein HSP 90-beta	Homo sapiens (human)
ficolin-1-rich granule lumen	Heat shock protein HSP 90-beta	Homo sapiens (human)
protein-containing complex	Heat shock protein HSP 90-beta	Homo sapiens (human)
aryl hydrocarbon receptor complex	Heat shock protein HSP 90-beta	Homo sapiens (human)
HSP90-CDC37 chaperone complex	Heat shock protein HSP 90-beta	Homo sapiens (human)
perinuclear region of cytoplasm	Heat shock protein HSP 90-beta	Homo sapiens (human)
plasma membrane	Heat shock protein HSP 90-beta	Homo sapiens (human)
cytosol	Heat shock protein HSP 90-beta	Homo sapiens (human)
extracellular region	Cholesteryl ester transfer protein	Homo sapiens (human)
extracellular space	Cholesteryl ester transfer protein	Homo sapiens (human)
vesicle	Cholesteryl ester transfer protein	Homo sapiens (human)
extracellular exosome	Cholesteryl ester transfer protein	Homo sapiens (human)
high-density lipoprotein particle	Cholesteryl ester transfer protein	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
nucleus	Lysine-specific demethylase 5A	Homo sapiens (human)
nucleoplasm	Lysine-specific demethylase 5A	Homo sapiens (human)
nucleolus	Lysine-specific demethylase 5A	Homo sapiens (human)
nucleus	Lysine-specific demethylase 5A	Homo sapiens (human)
chromatin	Lysine-specific demethylase 5A	Homo sapiens (human)
sarcoplasmic reticulum lumen	Endoplasmin	Canis lupus familiaris (dog)
melanosome	Endoplasmin	Canis lupus familiaris (dog)
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
nucleus	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
nucleoplasm	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
cytoplasm	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
cytosol	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
nuclear body	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
nuclear speck	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
motile cilium	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
axon cytoplasm	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
chromatin	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
euchromatin	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
protein-containing complex	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
RNA polymerase II transcription regulator complex	Hypoxia-inducible factor 1-alpha	Homo sapiens (human)
nucleoplasm	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
cytosol	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
nuclear speck	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
chromatin	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
transcription regulator complex	Endothelial PAS domain-containing protein 1	Homo sapiens (human)
nucleoplasm	Lysine-specific demethylase 4C	Homo sapiens (human)
chromatin	Lysine-specific demethylase 4C	Homo sapiens (human)
pericentric heterochromatin	Lysine-specific demethylase 4C	Homo sapiens (human)
nucleus	Lysine-specific demethylase 4C	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (120)

Assay ID	Title	Year	Journal	Article
AID350571	Cytotoxicity against human MCF7 cells after 72 hrs by celltiter-glo assay	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Potent cytotoxic C-11 modified geldanamycin analogues.
AID395892	Binding affinity to Hsp90 in human SKBR3 cells	2009	Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6	Discovery and development of heat shock protein 90 inhibitors.
AID266548	Inhibition of human SKBR3 cell growth	2006	Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15	Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
AID394603	Cytotoxicity against human MCF7 cells after 72 hrs	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Potent non-benzoquinone ansamycin heat shock protein 90 inhibitors from genetic engineering of Streptomyces hygroscopicus.
AID394598	Binding affinity to human recombinant Hsp90alpha N-terminal domain by scintillation proximity assay	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Potent non-benzoquinone ansamycin heat shock protein 90 inhibitors from genetic engineering of Streptomyces hygroscopicus.
AID1212925	Metabolic stability in human liver microsomes at 5 uM by liquid chromatography-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.
AID444597	Hepatic clearance in human liver microsomes measured per million cells	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Dihydroxyphenylisoindoline amides as orally bioavailable inhibitors of the heat shock protein 90 (hsp90) molecular chaperone.
AID327963	Inhibition of TNF-alpha-induced NF-kappaB activation in human HeLa cells	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Hypoxia-inducible factor-1 and nuclear factor-kappaB inhibitory meroterpene analogues of bakuchiol, a constituent of the seeds of Psoralea corylifolia.
AID465321	Toxicity in iv dosed dog assessed as maximum tolerated dose	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Heat shock protein 90: inhibitors in clinical trials.
AID394604	Cytotoxicity against NQ01-deficient human MDA468 cells after 72 hrs	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Potent non-benzoquinone ansamycin heat shock protein 90 inhibitors from genetic engineering of Streptomyces hygroscopicus.
AID344857	Cytotoxicity against human A2058 cells by MTT assay	2008	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23	Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone.
AID291918	Viability of human Hep3B cells under normoxic conditions after 24 hrs by MTT assay	2007	Journal of natural products, Jul, Volume: 70, Issue:7	Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1.
AID1076811	Antiproliferative activity against human SKBR3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6	Synthesis and evaluation of a novel class Hsp90 inhibitors containing 1-phenylpiperazine scaffold.
AID1076810	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6	Synthesis and evaluation of a novel class Hsp90 inhibitors containing 1-phenylpiperazine scaffold.
AID1127400	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	2014	European journal of medicinal chemistry, May-22, Volume: 79	Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening.
AID394605	Cytotoxicity against NQ01-deficient human NCI-H596 cells after 72 hrs	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Potent non-benzoquinone ansamycin heat shock protein 90 inhibitors from genetic engineering of Streptomyces hygroscopicus.
AID1127401	Antiproliferative activity against human A231 cells after 48 hrs by MTT assay	2014	European journal of medicinal chemistry, May-22, Volume: 79	Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening.
AID1885316	Inhibition of KDM5A (unknown origin) measured by AlphaScreen assay	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Recent Advances with KDM4 Inhibitors and Potential Applications.
AID506585	Inhibition of HSP90-mediated proliferation of human NCI-H526 cells at 1 uM after 96 hrs by sulforhodamine B assay	2007	Nature chemical biology, Aug, Volume: 3, Issue:8	Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer.
AID1625290	Inhibition of Hsp90 in human SKBR3 cells	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.
AID327961	Inhibition of hypoxia-induced HIF1 activation in human AGS cells by reporter gene assay	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Hypoxia-inducible factor-1 and nuclear factor-kappaB inhibitory meroterpene analogues of bakuchiol, a constituent of the seeds of Psoralea corylifolia.
AID1212926	Terminal half life in human	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.
AID344856	Inhibition of Hsp90 in human A2058 cells assessed as Akt degradation	2008	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23	Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone.
AID715287	Inhibition of Hsp90 in human COLO205 cells xenografted in mouse assessed as Her2 degradation at 100 mg/kg administered QD for 2 days measured 8 hrs post-last dose	2012	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17	Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90.
AID1212959	Drug metabolism assessed as human recombinant CYP3A5-mediated (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(2-(dimethylamino)ethylamino)-13-hydroxy-10-(hydroxymethyl)-8,14-dimethoxy-4,12,16-trimethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-penta	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.
AID1212974	Drug metabolism in human liver microsomes assessed as 1 uM CYP3A inhibitor ketoconazole-mediated inhibition of (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(2-(dimethylamino)-1-hydroxyethylamino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-a	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.
AID266550	Degradation of Her2 in SKBR3 cells	2006	Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15	Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
AID1212960	Drug metabolism assessed as human recombinant CYP3A5-mediated (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(2-(dimethylamino)-1-hydroxyethylamino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.
AID394600	Cytotoxicity against human SKBR3 cells after 72 hrs	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Potent non-benzoquinone ansamycin heat shock protein 90 inhibitors from genetic engineering of Streptomyces hygroscopicus.
AID1212969	Drug metabolism assessed as human recombinant CYP2B6-mediated oxidative metabolism at 1 uM by liquid chromatography-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.
AID266553	Upregulation of Hsp70 in SKOV3 cells	2006	Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15	Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
AID465320	Toxicity in iv dosed rat assessed as maximum tolerated dose	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Heat shock protein 90: inhibitors in clinical trials.
AID1212975	Drug metabolism in human liver microsomes assessed as 1 uM CYP3A inhibitor ketoconazole-mediated inhibition of (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(2-(dimethylamino)ethylamino)-13,14-dihydroxy-8-methoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.
AID1212961	Drug metabolism assessed as human recombinant CYP3A5-mediated (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(2-(dimethylamino)ethylamino)-13,14-dihydroxy-8-methoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbam	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.
AID1625300	Cytotoxicity against HGF-induced erlotinib-resistant human Ma1 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.
AID485532	Inhibition of hypoxia-induced VEGF protein secretion in human Hep3B cells after 16 hrs by ELISA	2010	Journal of natural products, Jun-25, Volume: 73, Issue:6	An isoaurone and other constituents from Trichosanthes kirilowii seeds inhibit hypoxia-inducible factor-1 and nuclear factor-kappaB.
AID344858	Inhibition of Hsp90 in human A2058 cells	2008	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23	Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone.
AID1212956	Drug metabolism in human liver microsomes assessed as (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(2-(dimethylamino)ethylamino)-8,13-dihydroxy-14-methoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate form	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.
AID1127395	Inhibition of HSP90 (unknown origin)-mediated ATPase activity at 40 uM after 3 hrs by malachite green assay relative to control	2014	European journal of medicinal chemistry, May-22, Volume: 79	Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening.
AID1127397	Displacement of FITC-geldanamycin from HSP90 (unknown origin) after 30 mins by fluorescence polarization assay	2014	European journal of medicinal chemistry, May-22, Volume: 79	Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening.
AID1212927	Total clearance in human	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.
AID1076813	Inhibition of full-length Hsp90-ATPase activity (unknown origin) assessed as inhibition of ATP hydrolysis by spectrophotometry	2014	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6	Synthesis and evaluation of a novel class Hsp90 inhibitors containing 1-phenylpiperazine scaffold.
AID1632347	Inhibition of 6x-His tagged human recombinant full length Hsp90alpha ATPase preincubated for 0.5 hrs followed by ATP addition measured after 30 mins by HTRF assay	2016	Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19	Structure-activity relationship of Garcinia xanthones analogues: Potent Hsp90 inhibitors with cytotoxicity and antiangiogenesis activity.
AID350574	Cytotoxicity against human CCRF-CEM cells after 72 hrs by celltiter-96 aqueous one solution assay	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Potent cytotoxic C-11 modified geldanamycin analogues.
AID1212962	Drug metabolism assessed as human recombinant CYP3A5-mediated (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(2-(dimethylamino)ethylamino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbam	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.
AID596788	Displacement of [3H]-(R)-2-(5-chloro-2,4-dihydroxybenzoyl)-N-ethylisoindoline-1-carboxamide from human his(6)-tagged HSP90alpha after 30 mins by scintillation proximity assay	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difl
AID394601	Cytotoxicity against human SKOV3 cells after 72 hrs	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Potent non-benzoquinone ansamycin heat shock protein 90 inhibitors from genetic engineering of Streptomyces hygroscopicus.
AID266546	Inhibition of BODIPY-AG binding to human HSP90	2006	Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15	Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
AID266547	Inhibition of BODIPY-AG binding to dog Grp94	2006	Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15	Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
AID394602	Cytotoxicity against human HCT116 cells after 72 hrs	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Potent non-benzoquinone ansamycin heat shock protein 90 inhibitors from genetic engineering of Streptomyces hygroscopicus.
AID1127396	Inhibition of full-length HSP90 (unknown origin) expressed in Escherichia coli assessed as inhibition of ATPase activity after 3 hrs by spectrophotometric analysis	2014	European journal of medicinal chemistry, May-22, Volume: 79	Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening.
AID344855	Cytotoxicity against human MDA-MB-231 cells by MTT assay	2008	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23	Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone.
AID422512	Inhibition of hypoxia-induced VEGF protein secretion in human Hep3B cells after 16 hrs by ELISA	2009	Journal of natural products, Jan, Volume: 72, Issue:1	Hypoxia-inducible factor-1 inhibitory benzofurans and chalcone-derived diels-alder adducts from Morus species.
AID1451199	Cytotoxicity against mouse primary hepatocytes assessed as reduction in cell viability at 5 to 20 uM after 24 hrs by MTT assay	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Paralog Specificity Determines Subcellular Distribution, Action Mechanism, and Anticancer Activity of TRAP1 Inhibitors.
AID1451185	Inhibition of HSP90 in human HeLa cells assessed as induction of Akt degradation at 10 uM after 6 hrs by Western blot method	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Paralog Specificity Determines Subcellular Distribution, Action Mechanism, and Anticancer Activity of TRAP1 Inhibitors.
AID1212937	Drug metabolism in human liver microsomes assessed as (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(2-(dimethylamino)ethylamino)-13,14-dihydroxy-8-methoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate form	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.
AID1212970	Drug metabolism assessed as human recombinant CYP2C9-mediated oxidative metabolism at 1 uM by liquid chromatography-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.
AID715289	Inhibition of Hsp90 in human COLO205 cells xenografted in mouse assessed as Raf1 degradation at 100 mg/kg administered QD for 2 days measured 8 hrs post-last dose	2012	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17	Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90.
AID291914	Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay	2007	Journal of natural products, Jul, Volume: 70, Issue:7	Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1.
AID1212928	Drug metabolism in human liver microsomes assessed as stability after 2 hrs relative to control by liquid chromatography-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.
AID1212953	Drug metabolism in human liver microsomes assessed as (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(2-(dimethylamino)-1-hydroxyethylamino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carb	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.
AID255773	Cytotoxicity against SKBr3 cells	2005	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22	Structure-based design of 7-carbamate analogs of geldanamycin.
AID350567	Cytotoxicity against human SKBR3 cells after 72 hrs by celltiter-glo assay	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Potent cytotoxic C-11 modified geldanamycin analogues.
AID1127398	Antiproliferative activity against human SKBR3 cells after 48 hrs by MTT assay	2014	European journal of medicinal chemistry, May-22, Volume: 79	Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening.
AID1212957	Drug metabolism in human liver microsomes assessed as (4E,6Z,8S,9S,10E,12R,13R,14S,16R)-19-(2-(dimethylamino)-1-hydroxyethylamino)-13-hydroxy-12,16-bis(hydroxymethyl)-8,14-dimethoxy-4,10-dimethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-p	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.
AID1212955	Drug metabolism in human liver microsomes assessed as (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(2-(dimethylamino)ethylamino)-13,14-dihydroxy-8-methoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate form	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.
AID485530	Inhibition of hypoxia-induced HIF1alpha protein accumulation in human Hep3B cells treated for 30 mins measured after 12 hrs by Western blot analysis	2010	Journal of natural products, Jun-25, Volume: 73, Issue:6	An isoaurone and other constituents from Trichosanthes kirilowii seeds inhibit hypoxia-inducible factor-1 and nuclear factor-kappaB.
AID1451184	Inhibition of HSP90 in human HeLa cells assessed as induction of chk1 degradation at 10 uM after 6 hrs by Western blot method	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Paralog Specificity Determines Subcellular Distribution, Action Mechanism, and Anticancer Activity of TRAP1 Inhibitors.
AID699452	Inhibition of luciferase activity in human LN229-Lux cells at 2.5 to 10 uM incubated for 1 hr under normoxia followed by 24 hrs under hypoxia by reporter gene assay	2012	Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15	Design and in vitro activities of N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl]heteroarylsulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents.
AID266549	Inhibition of human SKOV3 cell growth	2006	Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15	Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
AID422513	Inhibition of hypoxia-induced HIF1 activation in human Hep3B cells by pGL3-HRE-luciferase reporter gene assay	2009	Journal of natural products, Jan, Volume: 72, Issue:1	Hypoxia-inducible factor-1 inhibitory benzofurans and chalcone-derived diels-alder adducts from Morus species.
AID1451187	Inhibition of HSP90 in human PC3 cells assessed as induction of chk1 degradation at 10 uM after 6 hrs by Western blot method	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Paralog Specificity Determines Subcellular Distribution, Action Mechanism, and Anticancer Activity of TRAP1 Inhibitors.
AID596787	Inhibition of human HSP90 in human NCI-H1299 cells assessed as Akt degradation after 24 hrs by luminex assay	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difl
AID1212973	Drug metabolism in human liver microsomes assessed as 1 uM CYP3A inhibitor ketoconazole-mediated inhibition of (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(2-(dimethylamino)ethylamino)-13-hydroxy-10-(hydroxymethyl)-8,14-dimethoxy-4,12,16-trimethyl-3,20,22-trioxo	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.
AID1127399	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	2014	European journal of medicinal chemistry, May-22, Volume: 79	Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening.
AID506584	Binding affinity to HSP90 in human NCI-H526 cells at 1 uM after 24 hrs by fluorescence polarization assay	2007	Nature chemical biology, Aug, Volume: 3, Issue:8	Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer.
AID350575	Cytotoxicity against human paclitaxel-resistant CCRF-CEM cells after 72 hrs by celltiter-96 aqueous one solution assay	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Potent cytotoxic C-11 modified geldanamycin analogues.
AID1212963	Drug metabolism assessed as human recombinant CYP3A5-mediated (4E,6Z,8S,9S,10E,12R,13R,14S,16R)-19-(2-(dimethylamino)-1-hydroxyethylamino)-13-hydroxy-12,16-bis(hydroxymethyl)-8,14-dimethoxy-4,10-dimethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.
AID350572	Cytotoxicity against human SKOV3 cells after 72 hrs by celltiter-glo assay	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Potent cytotoxic C-11 modified geldanamycin analogues.
AID1212954	Drug metabolism in human liver microsomes assessed as (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(2-(dimethylamino)ethylamino)-13-hydroxy-10-(hydroxymethyl)-8,14-dimethoxy-4,12,16-trimethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.
AID1451186	Inhibition of HSP90 in human HeLa cells assessed as induction of HSP70 protein expression at 10 uM after 6 hrs by Western blot method	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Paralog Specificity Determines Subcellular Distribution, Action Mechanism, and Anticancer Activity of TRAP1 Inhibitors.
AID1170900	Reduction in oxygen consumption rate in human NCI-H1299 cells incubated for 12 hrs	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Discovery and optimization of 4,5-diarylisoxazoles as potent dual inhibitors of pyruvate dehydrogenase kinase and heat shock protein 90.
AID1451189	Inhibition of HSP90 in human PC3 cells assessed as induction of HSP70 protein expression at 10 uM after 6 hrs by Western blot method	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Paralog Specificity Determines Subcellular Distribution, Action Mechanism, and Anticancer Activity of TRAP1 Inhibitors.
AID580563	Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days by qRT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID350568	Binding affinity to human recombinant HSP90	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Potent cytotoxic C-11 modified geldanamycin analogues.
AID266551	Degradation of Her2 in SKOV3 cells	2006	Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15	Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
AID1212976	Drug metabolism in human liver microsomes assessed as 1 uM CYP3A inhibitor ketoconazole-mediated inhibition of (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(2-(dimethylamino)ethylamino)-8,13-dihydroxy-14-methoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.
AID444594	Displacement of [3H]pGA from His-tagged Hsp90 by scintillation proximity assay	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Dihydroxyphenylisoindoline amides as orally bioavailable inhibitors of the heat shock protein 90 (hsp90) molecular chaperone.
AID394593	Cytotoxicity against human SKBR3 cells after 72 hrs in presence of NQO1 inhibitor dicoumarol	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Potent non-benzoquinone ansamycin heat shock protein 90 inhibitors from genetic engineering of Streptomyces hygroscopicus.
AID344853	Inhibition of Hsp90 in human MDA-MB-231 cells assessed as Akt degradation	2008	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23	Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone.
AID1076812	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6	Synthesis and evaluation of a novel class Hsp90 inhibitors containing 1-phenylpiperazine scaffold.
AID344854	Inhibition of Hsp90 in human MDA-MB-231 cells assessed as her2 degradation	2008	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23	Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone.
AID499473	Binding affinity to Hsp90 N-terminal ATPase domain by isothermal titration calorimetry assay	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.
AID1885314	Inhibition of KDM4B (unknown origin) measured by AlphaScreen assay	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Recent Advances with KDM4 Inhibitors and Potential Applications.
AID1451188	Inhibition of HSP90 in human PC3 cells assessed as induction of Akt degradation at 10 uM after 6 hrs by Western blot method	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Paralog Specificity Determines Subcellular Distribution, Action Mechanism, and Anticancer Activity of TRAP1 Inhibitors.
AID291915	Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay	2007	Journal of natural products, Jul, Volume: 70, Issue:7	Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1.
AID465282	Chemical stability assessed as half life	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Heat shock protein 90: inhibitors in clinical trials.
AID394592	Cytotoxicity against human MCF7 cells after 72 hrs in presence of NQO1 inhibitor dicoumarol	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Potent non-benzoquinone ansamycin heat shock protein 90 inhibitors from genetic engineering of Streptomyces hygroscopicus.
AID327962	Cytotoxicity against human AGS cells by MTT assay	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Hypoxia-inducible factor-1 and nuclear factor-kappaB inhibitory meroterpene analogues of bakuchiol, a constituent of the seeds of Psoralea corylifolia.
AID1625299	Cytotoxicity against HGF-induced erlotinib-resistant human PC9 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.
AID394599	Binding affinity to human recombinant Hsp90alpha N-terminal domain by isothermal titration calorimetry	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Potent non-benzoquinone ansamycin heat shock protein 90 inhibitors from genetic engineering of Streptomyces hygroscopicus.
AID1212977	Drug metabolism in human liver microsomes assessed as 1 uM CYP3A inhibitor ketoconazole-mediated inhibition of (4E,6Z,8S,9S,10E,12R,13R,14S,16R)-19-(2-(dimethylamino)-1-hydroxyethylamino)-13-hydroxy-12,16-bis(hydroxymethyl)-8,14-dimethoxy-4,10-dimethyl-3,	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.
AID266552	Upregulation of Hsp70 in SKBR3 cells	2006	Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15	Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
AID596978	Toxicity in human A2058 cells xenografted po dosed nu/nu athymic mouse	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difl
AID1212971	Drug metabolism assessed as human recombinant CYP2E1-mediated oxidative metabolism at 1 uM by liquid chromatography-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.
AID580560	Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 nM HCV-796 and 800 nM boceprevir by qRT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID1212936	Drug metabolism in human liver microsomes assessed as (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(2-(dimethylamino)ethylamino)-13-hydroxy-10-(hydroxymethyl)-8,14-dimethoxy-4,12,16-trimethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.
AID1451198	Cytotoxicity against human corneal cells assessed as reduction in cell viability at 5 to 20 uM after 24 hrs by MTT assay	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Paralog Specificity Determines Subcellular Distribution, Action Mechanism, and Anticancer Activity of TRAP1 Inhibitors.
AID580561	Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 nM HCV-796 and 800 nM boceprevir by qRT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID1885315	Inhibition of KDM4C (unknown origin) measured by AlphaScreen assay	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Recent Advances with KDM4 Inhibitors and Potential Applications.
AID291916	Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay	2007	Journal of natural products, Jul, Volume: 70, Issue:7	Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1.
AID350573	Cytotoxicity against human A549 cells after 72 hrs by celltiter-glo assay	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Potent cytotoxic C-11 modified geldanamycin analogues.
AID254267	Binding affinity for human heat shock protein 90 in scintillation proximity assay	2005	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22	Structure-based design of 7-carbamate analogs of geldanamycin.
AID596793	Intrinsic clearance in human liver microsomes at 1 uM after 45 mins by LC MS/MS analysis	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difl
AID444595	Inhibition of Hsp90 in human H1299 assessed as degradation of Hsp90 client protein Akt	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Dihydroxyphenylisoindoline amides as orally bioavailable inhibitors of the heat shock protein 90 (hsp90) molecular chaperone.
AID422511	Inhibition of hypoxia-induced HIF1alpha protein accumulation in human Hep3B cells treated for 30 mins measured after 12 hrs by Western blot analysis	2009	Journal of natural products, Jan, Volume: 72, Issue:1	Hypoxia-inducible factor-1 inhibitory benzofurans and chalcone-derived diels-alder adducts from Morus species.
AID1885317	Inhibition of KDM6B (unknown origin) measured by AlphaScreen assay	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Recent Advances with KDM4 Inhibitors and Potential Applications.
AID596980	Antitumor activity against human A2058 cells xenografted in nu/nu athymic mouse model assessed as inhibition of tumor growth at 10 mg/kg, ip bid for 14 days	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difl
AID327964	Cytotoxicity against human HeLa cells by MTT assay	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Hypoxia-inducible factor-1 and nuclear factor-kappaB inhibitory meroterpene analogues of bakuchiol, a constituent of the seeds of Psoralea corylifolia.
AID499474	Cytotoxicity against human HCT116 cells by Alamar blue assay	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	68 (26.77)	29.6817
2010's	164 (64.57)	24.3611
2020's	22 (8.66)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	9 (3.53%)	5.53%
Reviews	14 (5.49%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	232 (90.98%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
adenine [no description available]	4.63	4	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
dimethyl sulfoxide Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.	2.05	1	0	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
glycine [no description available]	3.18	1	0	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
niacinamide nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.	2.51	2	0	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
phosphorylcholine Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.. phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.	2.04	1	0	phosphocholines	allergen; epitope; hapten; human metabolite; mouse metabolite
purine 1H-purine : The 1H-tautomer of purine.. 3H-purine : The 3H-tautomer of purine.. 9H-purine : The 9H-tautomer of purine.. 7H-purine : The 7H-tautomer of purine.	2.05	1	0	purine
benzamide benzamide : An aromatic amide that consists of benzene bearing a single carboxamido substituent. The parent of the class of benzamides.	2.05	1	0	benzamides
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	2.47	2	0	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
ciclopirox [no description available]	3.51	1	0	cyclic hydroxamic acid; hydroxypyridone antifungal drug; pyridone	antibacterial agent; antiseborrheic
deferiprone Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.. deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.	3.51	1	0	4-pyridones	iron chelator; protective agent
deferoxamine Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.	3.51	1	0	acyclic desferrioxamine	bacterial metabolite; ferroptosis inhibitor; iron chelator; siderophore
carbonyl cyanide p-trifluoromethoxyphenylhydrazone Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone: A proton ionophore that is commonly used as an uncoupling agent in biochemical studies.. carbonyl cyanide p-trifluoromethoxyphenylhydrazone : A hydrazone that is hydrazonomalononitrile in which one of the hydrazine hydrogens is substituted by a p-trifluoromethoxyphenyl group.	2.15	1	0	aromatic ether; hydrazone; nitrile; organofluorine compound	ATP synthase inhibitor; geroprotector; ionophore
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	2.51	2	0	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
staurosporine aglycone staurosporine aglycone: metabolite from culture broth of Nocardiopsis sp.; a neurotrophin antag; inhibits BDNF TrkB receptor	2.05	1	0
kinetin Kinetin: A furanyl adenine found in PLANTS and FUNGI. It has plant growth regulation effects.. cytokinin : A phytohormone that promote cell division, or cytokinesis, in plant roots and shoots.. kinetin : A member of the class of 6-aminopurines that is adenine carrying a (furan-2-ylmethyl) substituent at the exocyclic amino group.	2.03	1	0	6-aminopurines; furans	cytokinin; geroprotector
letrozole [no description available]	3.17	1	0	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
olomoucine olomoucine: inhibits protein P34CDC2. olomoucine : A 9H-purine that is substituted by a (2-hydroxyethyl)nitrilo, benzylnitrilo and a methyl group at positions 2,6 and 9, respectively. It is a cyclin-dependent kinase inhibitor.	2.03	1	0	2,6-diaminopurines; ethanolamines	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
quinone benzoquinone : The simplest members of the class of benzoquinones, consisting of cyclohexadiene which is substituted by two oxo groups.. 1,4-benzoquinone : The simplest member of the class of 1,4-benzoquinones, obtained by the formal oxidation of hydroquinone to the corresponding diketone. It is a metabolite of benzene.. quinone : Compounds having a fully conjugated cyclic dione structure, such as that of benzoquinones, derived from aromatic compounds by conversion of an even number of -CH= groups into -C(=O)- groups with any necessary rearrangement of double bonds (polycyclic and heterocyclic analogues are included).	2.06	1	0	1,4-benzoquinones	cofactor; human xenobiotic metabolite; mouse metabolite
potassium chloride Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.. potassium chloride : A metal chloride salt with a K(+) counterion.	2.06	1	0	inorganic chloride; inorganic potassium salt; potassium salt	fertilizer
prazosin Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.	2.03	1	0	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
resorcinol resorcinol: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7951. resorcinol : A benzenediol that is benzene dihydroxylated at positions 1 and 3.	2.05	1	0	benzenediol; phenolic donor; resorcinols	erythropoietin inhibitor; sensitiser
imatinib [no description available]	3.23	1	0	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	3.9	3	0	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
thiram Thiram: A dithiocarbamate chemical, used commercially in the rubber processing industry and as a fungicide. In vivo studies indicate that it inactivates the enzyme GLUTATHIONE REDUCTASE. It has mutagenic activity and may induce chromosomal aberrations.. thiram : An organic disulfide that results from the formal oxidative dimerisation of N,N-dimethyldithiocarbamic acid. It is widely used as a fungicidal seed treatment.	2.07	1	0	organic disulfide	antibacterial drug; antifungal agrochemical; antiseptic drug
thymidine [no description available]	2.02	1	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
lysine Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.	2.11	1	0	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
adenosine diphosphate Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.	2.03	1	0	adenosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite; human metabolite
kanamycin a Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.	2.11	1	0	kanamycins	bacterial metabolite
phenylephrine Phenylephrine: An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent.. phenylephrine : A member of the class of the class of phenylethanolamines that is (1R)-2-(methylamino)-1-phenylethan-1-ol carrying an additional hydroxy substituent at position 3 on the phenyl ring.	2.06	1	0	phenols; phenylethanolamines; secondary amino compound	alpha-adrenergic agonist; cardiotonic drug; mydriatic agent; nasal decongestant; protective agent; sympathomimetic agent; vasoconstrictor agent
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	2.48	2	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
arginine Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.	2.03	1	0	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
methyl chloroformate [no description available]	2.1	1	0
dichloroacetic acid [no description available]	2.1	1	0	monocarboxylic acid; organochlorine compound	astringent; marine metabolite
rotenone Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.	2.1	1	0	organic heteropentacyclic compound; rotenones	antineoplastic agent; metabolite; mitochondrial NADH:ubiquinone reductase inhibitor; phytogenic insecticide; piscicide; toxin
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	2.03	1	0	pyrrole; secondary amine
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.99	4	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
indazoles Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.	3.18	1	0	indazole
isoxazoles Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.	4.82	9	0	isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiazoles [no description available]	3.45	1	1	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
pyrazines Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.	2.49	2	0	diazine; pyrazines	Daphnia magna metabolite
deoxycytidine [no description available]	2.15	1	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
arsenic trioxide Arsenic Trioxide: An inorganic compound with the chemical formula As2O3 that is used for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA in patients who have relapsed from, or are resistant to, conventional drug therapy.	2.74	3	0
platinum Platinum: A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as alutiae.	2.08	1	0	elemental platinum; nickel group element atom; platinum group metal atom
nigericin Nigericin: A polyether antibiotic which affects ion transport and ATPase activity in mitochondria. It is produced by Streptomyces hygroscopicus. (From Merck Index, 11th ed). nigericin : A polyether antibiotic which affects ion transport and ATPase activity in mitochondria. It is produced by Streptomyces hygroscopicus.	2.25	1	0	polycyclic ether	antibacterial agent; antimicrobial agent; bacterial metabolite; potassium ionophore
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.11	1	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	2.15	1	0	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
toxoflavin toxoflavin: azapteridine antibiotic; structure. toxoflavin : A pyrimidotriazine that is 1,6-dimethyl-1,5,6,7-tetrahydropyrimido[5,4-e][1,2,4]triazine with oxo groups at positions 5 and 7.	3.51	1	0	carbonyl compound; pyrimidotriazine	antibacterial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite; toxin; virulence factor; Wnt signalling inhibitor
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	5.54	6	0	1,2,3-triazole
fluorodeoxyglucose f18 Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)	2.05	1	0	2-deoxy-2-((18)F)fluoro-D-glucose; 2-deoxy-2-fluoro-aldehydo-D-glucose
zoledronic acid Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.	2.13	1	0	1,1-bis(phosphonic acid); imidazoles	bone density conservation agent
fulvestrant Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.	3.61	2	0	17beta-hydroxy steroid; 3-hydroxy steroid; organofluorine compound; sulfoxide	antineoplastic agent; estrogen antagonist; estrogen receptor antagonist
Zearalanone [no description available]	3.14	1	0	macrolide; resorcinols
tanshinone tanshinone: from root of Salvia miltiorrhiza Bunge; RN given refers to tanshinone I; cardioprotective agent and neuroprotective agent	2.03	1	0	abietane diterpenoid	anticoronaviral agent
celastrol [no description available]	2.05	1	0	monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory drug; antineoplastic agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Hsp90 inhibitor; metabolite
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	2.44	2	0	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
gefitinib [no description available]	2.48	2	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
di-n-desethylamiodarone di-N-desethylamiodarone: amiodarone metabolite in dogs; structure given in first source	3.51	1	0
perifosine [no description available]	2.04	1	0	ammonium betaine; phospholipid	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
tanshinone vi tanshinone VI: isolated from the root of Salvia miltiorrhiza; structure in first source	2.03	1	0
atrasentan Atrasentan: A pyrrolidine and benzodioxole derivative that acts a RECEPTOR, ENDOTHELIN A antagonist. It has therapeutic potential as an antineoplastic agent and for the treatment of DIABETIC NEPHROPATHIES.	2.03	1	0	pyrrolidines
cryptotanshinone cryptotanshinone: from Salvia miltiorrhiza	2.03	1	0	abietane diterpenoid	anticoronaviral agent
tanshinone ii a tashinone IIA: a cardiovascular agent with antineoplastic activity; isolated from Salvia miltiorrhiza; structure in first source	2.03	1	0	abietane diterpenoid
angiotensin ii Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).	2.57	2	0	amino acid zwitterion; angiotensin II	human metabolite
erlotinib hydrochloride [no description available]	2.07	1	0	hydrochloride; terminal acetylenic compound	antineoplastic agent; protein kinase inhibitor
moracin m moracin M: has been isolated from Morus alba L.; structure in first source	2.05	1	0	benzofurans
deferasirox Deferasirox: A triazole and benzoate derivative that acts as a selective iron chelator. It is used in the management of chronic IRON OVERLOAD due to blood transfusion or non-transfusion dependent THALASSEMIA.. deferasirox : A member of the class of triazoles, deferasirox is 1,2,4-triazole substituted by a 4-carboxyphenyl group at position 1 and by 2-hydroxyphenyl groups at positions 3 and 5. An orally active iron chelator, it is used to manage chronic iron overload in patients receiving long-term blood transfusions.	3.51	1	0	benzoic acids; monocarboxylic acid; phenols; triazoles	iron chelator
sorafenib [no description available]	2.1	1	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
3-nitrotyrosine 3-nitrotyrosine: RN given refers to parent cpd without isomeric designation. 3-nitrotyrosine : A nitrotyrosine comprising tyrosine having a nitro group at the 3-position on the phenyl ring.	2.07	1	0	2-nitrophenols; C-nitro compound; nitrotyrosine; non-proteinogenic alpha-amino acid
withaferin a withaferin A: an antiestrogen and phytogenic antineoplastic agent isolated from leaves of Withania somnifera Dun.; structure. withaferin A : A withanolide that is 5,6:22,26-diepoxyergosta-2,24-diene-1,26-dione substituted by hydroxy groups at positions 4 and 27 (the 4beta,5beta,6beta,22R stereoisomer). Isolated from Physalis longifolia, it exhibits cytotoxic activity.	2.06	1	0	27-hydroxy steroid; 4-hydroxy steroid; delta-lactone; enone; epoxy steroid; ergostanoid; primary alcohol; secondary alcohol; withanolide	antineoplastic agent; apoptosis inducer
withanolides Withanolides: Ergostane derivatives of 28 carbons with oxygens at C1, C22, and C26 positions and the side chain cyclized. They are found in WITHANIA plant genus and have cytotoxic and other effects.	2.06	1	0
bortezomib [no description available]	2.49	2	0	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
leupeptins Leupeptins: A group of acylated oligopeptides produced by Actinomycetes that function as protease inhibitors. They have been known to inhibit to varying degrees trypsin, plasmin, KALLIKREINS, papain and the cathepsins.	2.11	1	0
trichostatin a trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES	3.82	2	0	antibiotic antifungal agent; hydroxamic acid; trichostatin	bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector
tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.	2.04	1	0	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
8-(2-chloro-3,4,5-trimethoxybenzyl)-2-fluoro-9-pent-4-yn-1-yl-9H-purin-6-amine 8-(2-chloro-3,4,5-trimethoxybenzyl)-2-fluoro-9-pent-4-yn-1-yl-9H-purin-6-amine : A member of the class of 6-aminopurines that is 2-fluoroadenine carrying additional 2-chloro-3,4,5-trimethoxybenzyl and pent-4-yn-1-yl substituents at positions 8 and 9 respectively.	3.14	1	0	6-aminopurines; acetylenic compound; methoxybenzenes; monochlorobenzenes; organofluorine compound	antineoplastic agent; Hsp90 inhibitor
5-carboxy-8-hydroxyquinoline 5-carboxy-8-hydroxyquinoline: a JmjC histone demethylase inhibitor; structure in first source	3.51	1	0	quinolines
benzyloxycarbonylleucyl-leucyl-leucine aldehyde benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor. N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative.	2.11	1	0	amino aldehyde; carbamate ester; tripeptide	proteasome inhibitor
2'-c-methylcytidine 2'-C-methylcytidine: structure in first source	2.05	1	0
cct018159 CCT018159: structure in first source. CCT-018159 : A member of the class of pyrazoles that is 1H-pyrazole carrying 1,4-benzodioxane-6-yl and 5-ethyl-2,4-dihydroxyphenyl substituents at positions 4 and 5 respectively.	3.58	2	0	benzodioxine; pyrazoles; resorcinols	antineoplastic agent; apoptosis inducer; Hsp90 inhibitor
n-glycylalanine Gly-Ala : A dipeptide formed from glycine and L-alanine residues.	2.05	1	0	dipeptide	metabolite
tamoxifen [no description available]	2.15	1	0	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
N-[2-furanyl-(8-hydroxy-7-quinolinyl)methyl]-2-methylpropanamide [no description available]	3.51	1	0	hydroxyquinoline
u 0126 U 0126: protein kinase kinase inhibitor; structure in first source	2.06	1	0	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
hcv 371 [no description available]	2.05	1	0
dasatinib N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).	3.45	1	1	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
ver-49009 VER-49009: inhibits heat shock protein 90 molecular chaperone; structure in first source. 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-(4-methoxyphenyl)pyrazole-3-carboxamide : An aromatic amide obtained by formal condensation of the carboxy group of 5-(5-chloro-2,4-dihydroxyphenyl)-4-(4-methoxyphenyl)pyrazole-3-carboxylic acid with the amino group of ethylamine.	3.14	1	0	aromatic amide; monochlorobenzenes; monomethoxybenzene; pyrazoles; resorcinols	Hsp90 inhibitor
osteoprotegerin Osteoprotegerin: A secreted member of the TNF receptor superfamily that negatively regulates osteoclastogenesis. It is a soluble decoy receptor of RANK LIGAND that inhibits both CELL DIFFERENTIATION and function of OSTEOCLASTS by inhibiting the interaction between RANK LIGAND and RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B.	2.15	1	0	long-chain fatty acid
quercetin [no description available]	2.98	4	0	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
dinoprost Dinoprost: A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.. prostaglandin F2alpha : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor.	2.15	1	0	monocarboxylic acid; prostaglandins Falpha	human metabolite; mouse metabolite
luteolin [no description available]	2.08	1	0	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist
vomifoliol blumenol A: a phytotoxin isolated from Oryza sativa Awaakamai; structure in first source. vomifoliol : A fenchane monoterpenoid that is 3,5,5-trimethylcyclohex-2-en-1-one substituted by a hydroxy and a (1E)-3-hydroxybut-1-en-1-yl group at position 4.. (6S,9R)-vomifoliol : A (6S)-vomifoliol with a R configuration for the hydroxy group at position 9.	2.05	1	0	(6S)-vomifoliol	metabolite; phytotoxin
geldanamycin [no description available]	10.41	7	0	1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound	antimicrobial agent; antineoplastic agent; antiviral agent; cysteine protease inhibitor; Hsp90 inhibitor
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	2.05	1	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
herbimycin herbimycin: herbicidal antibiotic produced by Streptomyces sp.; see also herbimycin B; structure for herbimycin A in second source. herbimycin : A 19-membered macrocyle incorporating a benzoquinone ring and a lactam functionality. It is an ansamycin antibiotic that induces apoptosis and displays antitumour effects.	2.03	1	0	1,4-benzoquinones; lactam; macrocycle	antimicrobial agent; apoptosis inducer; herbicide; Hsp90 inhibitor; tyrosine kinase inhibitor
arsenic Arsenic: A shiny gray element with atomic symbol As, atomic number 33, and atomic weight 75. It occurs throughout the universe, mostly in the form of metallic arsenides. Most forms are toxic. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), arsenic and certain arsenic compounds have been listed as known carcinogens. (From Merck Index, 11th ed)	2.74	3	0	metalloid atom; pnictogen	micronutrient
geldanamycin [no description available]	7.22	27	0
macbecin i macbecin I: from Norcardia sp. No. C-14919; belongs to ansamycin group of antibiotics; RN given refers to (6S,15R)-isomer; structure in second source	2.06	1	0
bakuchiol bakuchiol: chief component of Psoralea corylifolia Linn; structure	2.04	1	0
monorden monorden: inhibits HSP90 Heat-Shock Proteins, DNA topoisomerase VI and human Topoisomerase II	4.56	7	0	cyclic ketone; enone; epoxide; macrolide antibiotic; monochlorobenzenes; phenols	antifungal agent; metabolite; tyrosine kinase inhibitor
tanespimycin CP 127374: analog of herbimycin A	9.56	52	0	1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound; secondary amino compound	antineoplastic agent; apoptosis inducer; Hsp90 inhibitor
tubacin tubacin: inhibits histone deacetylase 6; structure in first source	2.59	2	0	1,3-oxazoles
pd 184352 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide: inhibits MAP kinase kinase; structure in first source	2.03	1	0	aminobenzoic acid
belinostat [no description available]	2.08	1	0	hydroxamic acid; olefinic compound; sulfonamide	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
9h-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-n-(1-methylethyl)- 9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)-: an epichaperome (purine-scaffold) inhibitor; structure in first source	4.08	4	0
cycloproparadicicol cycloproparadicicol: structure in first source	3.54	2	0
gambogic acid gambogic acid: RN given refers to (1R-(1alpha,1(Z),3abeta,5alpha,11beta,14aS*))-isomer	2.13	1	0	pyranoxanthones	metabolite
knk 437 KNK 437: inhibits thermotolerance acquisition and heat shock protein induction in colon carcinoma cells; structure in first source	2.44	2	0
ipi 493 17-aminogeldanamycin: structure in first source	2.95	4	0
n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide boceprevir : A synthetic tripeptide consisting of N-(tert-butylcarbamoyl)-3-methyl-L-valyl, a cyclopropyl-fused prolyl and 3-amino-4-cyclobutyl-2-oxobutanamide residues joined in sequence. Used for treatment of chronic hepatitis C virus genotype 1 infection.	2.05	1	0	tripeptide; ureas	antiviral drug; hepatitis C protease inhibitor; peptidomimetic
pochonin d pochonin D: secondary metabolite of Pochonia chlamydosporia; structure in first source	3.14	1	0
Dihydrotanshinone I dihydrotanshinone I: extracted from Radix Salviae	2.03	1	0	abietane diterpenoid	anticoronaviral agent
hcv 796 HCV 796: inhibits HCV RdRp; structure in first source	2.05	1	0
crizotinib Crizotinib: A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER.. crizotinib : A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)	3.23	1	0	3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine	antineoplastic agent; biomarker; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
at 13387 (2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone: structure in first source. onalespib : A member of the class of isoindoles that is isoindole in which the amino group has been acylated by a 2,4-dihydroxy-5-isopropylbenzoyl group and in which position 5 of the isoidole moiety has been substituted by a (4-methylpiperazin-1-yl)methyl group. A second-generation Hsp90 inhibitor.	3.88	3	0	benzamides; isoindoles; N-alkylpiperazine; resorcinols; tertiary carboxamide	antineoplastic agent; Hsp90 inhibitor
dactolisib dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR. dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.	2.25	1	0	imidazoquinoline; nitrile; quinolines; ring assembly; ureas	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
pituitrin Pituitrin: A substance or extract from the neurohypophysis (PITUITARY GLAND, POSTERIOR).	2.15	1	0
3,4-dimethoxy-n-((2,2-dimethyl-2h-chromen-6-yl)methyl)-n-phenylbenzenesulfonamide 3,4-dimethoxy-N-((2,2-dimethyl-2H-chromen-6-yl)methyl)-N-phenylbenzenesulfonamide: has antineoplastic activity; structure in first source	2.07	1	0
oligonucleotides [no description available]	2.11	1	0
endothelin-1 Endothelin-1: A 21-amino acid peptide produced in a variety of tissues including endothelial and vascular smooth-muscle cells, neurons and astrocytes in the central nervous system, and endometrial cells. It acts as a modulator of vasomotor tone, cell proliferation, and hormone production. (N Eng J Med 1995;333(6):356-63)	2.17	1	0
tg101209 [no description available]	3.06	1	0	N-alkylpiperazine; N-arylpiperazine; pyrimidines; secondary amino compound; sulfonamide	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
cnf 2024 [no description available]	4.09	4	0	2-aminopurines; aromatic ether; organochlorine compound; pyridines	antineoplastic agent; Hsp90 inhibitor
echinomycin Echinomycin: A cytotoxic polypeptide quinoxaline antibiotic isolated from Streptomyces echinatus that binds to DNA and inhibits RNA synthesis.	2.79	3	0	cyclodepsipeptide
olaparib [no description available]	2.47	2	0	cyclopropanes; monofluorobenzenes; N-acylpiperazine; phthalazines	antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
snx 2112 SNX 2112: an orally available small molecule Hsp90 inhibitor; structure in first source	2.78	3	0
incb-018424 [no description available]	3.06	1	0	nitrile; pyrazoles; pyrrolopyrimidine	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
ver 155008 VER 155008: structure in first source	2.08	1	0	purine nucleoside
nvp-bep800 [no description available]	2.05	1	0
plx4032 [no description available]	3.23	1	0	aromatic ketone; difluorobenzene; monochlorobenzenes; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor
debio 0932 CUDC 305: an Hsp90 inhibitor with antineoplastic activity; structure in first source	2.17	1	0
pf 04929113 [no description available]	3.18	1	0
piperidines Piperidines: A family of hexahydropyridines.	2.1	1	0
interleukin-8 Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.	2.1	1	0
alectinib [no description available]	2.1	1	0	aromatic ketone; morpholines; nitrile; organic heterotetracyclic compound; piperidines	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
novobiocin Novobiocin: An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189). novobiocin : A coumarin-derived antibiotic obtained from Streptomyces niveus.	3.13	1	0	carbamate ester; ether; hexoside; hydroxycoumarin; monocarboxylic acid amide; monosaccharide derivative; phenols	antibacterial agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Escherichia coli metabolite; hepatoprotective agent
dicumarol Dicumarol: An oral anticoagulant that interferes with the metabolism of vitamin K. It is also used in biochemical experiments as an inhibitor of reductases.	2.11	1	0	hydroxycoumarin	anticoagulant; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; Hsp90 inhibitor; vitamin K antagonist
epidermal growth factor Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.	2.46	2	0
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	3.74	3	0
xl 888 XL 888: structure in first source	2.07	1	0
imetelstat [no description available]	2.11	1	0
cyclin d1 Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.	2.07	1	0
transforming growth factor alpha Transforming Growth Factor alpha: An EPIDERMAL GROWTH FACTOR related protein that is found in a variety of tissues including EPITHELIUM, and maternal DECIDUA. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form which binds to the EGF RECEPTOR.	2.1	1	0
akt-i-1,2 compound Akt-I-1,2 compound: an aminopeptidase P inhibitor; structure in first source	2.03	1	0
nu 1025 NU 1064: structure in first source	2.47	2	0	phenols; quinazolines	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
3-methyladenine N3-methyladenine: structure in first source	2.05	1	0
ver-50589 VER-50589: inhibits heat shock protein 90 molecular chaperone; structure in first source	3.14	1	0
n,n'-monomethylenebis(pyridiniumaldoxime) N,N'-monomethylenebis(pyridiniumaldoxime): RN given refers to parent cpd	2.1	1	0
ver 52296 luminespib : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-(2,4-dihydroxy-5-isopropylphenyl)-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxylic acid with the amino group of ethylamine.	4.61	4	0	aromatic amide; isoxazoles; monocarboxylic acid amide; morpholines; resorcinols	angiogenesis inhibitor; antineoplastic agent; Hsp90 inhibitor
sta 9090 [no description available]	5.32	6	0	ring assembly; triazoles

Condition	Indicated	Relationship Strength	Studies	Trials
Carcinoma, Oat Cell [description not available]	0	2.03	1	0
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	0	2.47	2	0
Cancer of Lung [description not available]	0	4.16	15	0
Lung Neoplasms Tumors or cancer of the LUNG.	0	4.16	15	0
Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)	0	2.03	1	0
Malignant Melanoma [description not available]	0	4.47	8	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	0	4.47	8	0
Benign Neoplasms [description not available]	0	10.97	26	6
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	10.97	26	6
Biliary Cirrhosis [description not available]	0	2.41	1	0
Liver Cirrhosis, Biliary FIBROSIS of the hepatic parenchyma due to obstruction of BILE flow (CHOLESTASIS) in the intrahepatic or extrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cholangitis involves the destruction of small intra-hepatic bile ducts and decreased bile secretion. Secondary biliary cholangitis is produced by prolonged obstruction of large intrahepatic or extrahepatic bile ducts from a variety of causes.	0	2.41	1	0
Agnogenic Myeloid Metaplasia [description not available]	0	4.21	9	0
Cirrhosis [description not available]	0	5.08	11	0
Enlarged Spleen [description not available]	0	4.21	9	0
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	0	5.08	11	0
Primary Myelofibrosis A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.	0	4.21	9	0
Hepatocellular Carcinoma [description not available]	0	4.29	6	0
Cancer of Liver [description not available]	0	4.71	10	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	0	4.29	6	0
Liver Neoplasms Tumors or cancer of the LIVER.	0	4.71	10	0
2019 Novel Coronavirus Disease [description not available]	0	2.6	1	0
Brain Hemorrhage, Cerebral [description not available]	0	2.82	2	0
Cerebral Hemorrhage Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA.	0	2.82	2	0
Hematoma A collection of blood outside the BLOOD VESSELS. Hematoma can be localized in an organ, space, or tissue.	0	2.6	1	0
Bone Cancer [description not available]	0	2.63	2	0
Osteogenic Sarcoma [description not available]	0	2.61	2	0
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	0	2.63	2	0
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	0	2.61	2	0
Autoimmune Disease [description not available]	0	4.2	3	0
Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.	0	4.2	3	0
Acute Lymphoid Leukemia [description not available]	0	2.88	3	0
Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.	0	2.88	3	0
Frostbite Damage to tissues as the result of low environmental temperatures.	0	2.25	1	0
Innate Inflammatory Response [description not available]	0	3.07	4	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	3.07	4	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	6.97	25	0
Alcoholic Cirrhosis [description not available]	0	2.25	1	0
Alcoholic Liver Diseases [description not available]	0	2.25	1	0
Liver Cirrhosis, Alcoholic FIBROSIS of the hepatic parenchyma due to chronic excess ALCOHOL DRINKING.	0	2.25	1	0
Liver Diseases, Alcoholic Liver diseases associated with ALCOHOLISM. It usually refers to the coexistence of two or more subentities, i.e., ALCOHOLIC FATTY LIVER; ALCOHOLIC HEPATITIS; and ALCOHOLIC CIRRHOSIS.	0	2.25	1	0
Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.	0	2.25	1	0
Bladder Cancer [description not available]	0	2.81	3	0
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	0	2.81	3	0
Encephalopathy, Traumatic [description not available]	0	3.17	1	0
Brain Injuries, Traumatic A form of acquired brain injury which occurs when a sudden trauma causes damage to the brain.	0	3.17	1	0
Lung Adenocarcinoma [description not available]	0	2.31	1	0
Adenocarcinoma of Lung A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.	0	2.31	1	0
Carcinoma, Squamous Cell of Head and Neck [description not available]	0	2.31	1	0
Cancer of Mouth [description not available]	0	2.31	1	0
Squamous Cell Carcinoma of Head and Neck The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.	0	2.31	1	0
Mouth Neoplasms Tumors or cancer of the MOUTH.	0	2.31	1	0
Cerebral Infarction, Middle Cerebral Artery [description not available]	0	2.57	2	0
Apoplexy [description not available]	0	2.31	1	0
Hyperglycemia, Postprandial Abnormally high BLOOD GLUCOSE level after a meal.	0	2.31	1	0
Hyperglycemia Abnormally high BLOOD GLUCOSE level.	0	2.31	1	0
Infarction, Middle Cerebral Artery NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.	0	2.57	2	0
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	0	2.31	1	0
Alveolitis, Fibrosing [description not available]	0	3.06	1	0
Sclerosis, Systemic [description not available]	0	3.44	2	0
Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.	0	3.06	1	0
Scleroderma, Systemic A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.	0	3.44	2	0
ER-Negative PR-Negative HER2-Negative Breast Cancer [description not available]	0	3.43	2	0
Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.	0	3.43	2	0
Polyarthritis [description not available]	0	2.17	1	0
Allodynia [description not available]	0	2.17	1	0
Ache [description not available]	0	2.49	2	0
Arthritis Acute or chronic inflammation of JOINTS.	0	2.17	1	0
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	0	2.49	2	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	0	2.47	2	0
Circoviridae Infections Virus diseases caused by the CIRCOVIRIDAE.	0	2.15	1	0
Bladder Neck Obstruction [description not available]	0	2.54	2	0
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	0	2.15	1	0
Hyponatremia Deficiency of sodium in the blood; salt depletion. (Dorland, 27th ed)	0	2.15	1	0
Leucocythaemia [description not available]	0	2.47	2	0
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	0	2.47	2	0
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	0	2.15	1	0
Breast Cancer [description not available]	0	5.01	14	0
Breast Neoplasms Tumors or cancer of the human BREAST.	1	7.01	14	0
Foot and Mouth Disease [description not available]	0	2.17	1	0
African Sleeping Sickness [description not available]	0	2.17	1	0
Plasmodium falciparum Malaria [description not available]	0	2.17	1	0
Trypanosomiasis, African A disease endemic among people and animals in Central Africa. It is caused by various species of trypanosomes, particularly T. gambiense and T. rhodesiense. Its second host is the TSETSE FLY. Involvement of the central nervous system produces African sleeping sickness. Nagana is a rapidly fatal trypanosomiasis of horses and other animals.	0	2.17	1	0
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	0	2.17	1	0
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	0	2.21	1	0
Pulmonary Arterial Remodeling [description not available]	0	2.25	1	0
Blood Pressure, High [description not available]	0	2.25	1	0
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	0	2.25	1	0
Carcinoma, Non-Small Cell Lung [description not available]	0	3.32	6	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	0	3.32	6	0
Acute Myelogenous Leukemia [description not available]	0	4.55	5	1
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	0	4.55	5	1
Anoxemia [description not available]	0	2.99	4	0
Cancer of Skin [description not available]	0	2.73	3	0
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	0	2.99	4	0
Skin Neoplasms Tumors or cancer of the SKIN.	0	2.73	3	0
Infections, Pseudomonas [description not available]	0	2.08	1	0
Keratitis Inflammation of the cornea.	0	2.08	1	0
Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS.	0	2.08	1	0
Colorectal Cancer [description not available]	0	2.76	3	0
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	0	2.76	3	0
Cancer of Ovary [description not available]	0	2.78	3	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	0	2.78	3	0
Retinal Degeneration A retrogressive pathological change in the retina, focal or generalized, caused by genetic defects, inflammation, trauma, vascular disease, or aging. Degeneration affecting predominantly the macula lutea of the retina is MACULAR DEGENERATION. (Newell, Ophthalmology: Principles and Concepts, 7th ed, p304)	0	2.08	1	0
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	0	2.48	2	0
Idiopathic Parkinson Disease [description not available]	0	2.1	1	0
Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	0	2.1	1	0
Autosomal Dominant Striatonigral Degeneration [description not available]	0	2.1	1	0
Machado-Joseph Disease A dominantly-inherited ATAXIA first described in people of Azorean and Portuguese descent, and subsequently identified in Brazil, Japan, China, and Australia. This disorder is classified as one of the SPINOCEREBELLAR ATAXIAS (Type 3) and has been associated with a mutation of the MJD1 gene on chromosome 14. Clinical features include progressive ataxia, DYSARTHRIA, postural instability, nystagmus, eyelid retraction, and facial FASCICULATIONS. DYSTONIA is prominent in younger patients (referred to as Type I Machado-Joseph Disease). Type II features ataxia and ocular signs; Type III features MUSCULAR ATROPHY and a sensorimotor neuropathy; and Type IV features extrapyramidal signs combined with a sensorimotor neuropathy. (From Clin Neurosci 1995;3(1):17-22; Ann Neurol 1998 Mar;43(3):288-96)	0	2.1	1	0
Disease Exacerbation [description not available]	0	2.78	3	0
Dyskinesia Syndromes [description not available]	0	2.1	1	0
Dementias, Transmissible [description not available]	0	2.1	1	0
Movement Disorders Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.	0	2.1	1	0
Pemphigoid [description not available]	0	3.42	2	0
Pemphigoid, Bullous A chronic and relatively benign subepidermal blistering disease usually of the elderly and without histopathologic acantholysis.	0	3.42	2	0
Alcoholic Fatty Liver [description not available]	0	2.1	1	0
Sarcoma, Small Cell A sarcoma characterized by the presence of small cells, cells measuring 9-14 micrometers with a faint or indistinct rim of cytoplasm and an oval-to-elongated nucleus with relatively dense chromatin. (From Segen, Dictionary of Modern Medicine, 1992)	0	2.1	1	0
Burns Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like.	0	2.1	1	0
Cancer of Colon [description not available]	0	2.48	2	0
Colonic Neoplasms Tumors or cancer of the COLON.	0	2.48	2	0
Aneurysm, Aortic [description not available]	0	2.11	1	0
Angiogenesis, Pathologic [description not available]	0	3.15	5	0
Aortic Aneurysm An abnormal balloon- or sac-like dilatation in the wall of AORTA.	0	2.11	1	0
Acquired Form of Epidermolysis Bullosa [description not available]	0	3.7	3	0
Epidermolysis Bullosa Acquisita Form of epidermolysis bullosa characterized by trauma-induced, subepidermal blistering with no family history of the disease. Direct immunofluorescence shows IMMUNOGLOBULIN G deposited at the dermo-epidermal junction.	0	3.7	3	0
Caliciviridae Infections Virus diseases caused by CALICIVIRIDAE. They include HEPATITIS E; VESICULAR EXANTHEMA OF SWINE; acute respiratory infections in felines, rabbit hemorrhagic disease, and some cases of gastroenteritis in humans.	0	2.11	1	0
Invasiveness, Neoplasm [description not available]	0	2.48	2	0
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	0	2.47	2	0
Bullous Dermatoses [description not available]	0	3.03	1	0
Duhring Disease [description not available]	0	3.03	1	0
Dermatitis Herpetiformis Rare, chronic, papulo-vesicular disease characterized by an intensely pruritic eruption consisting of various combinations of symmetrical, erythematous, papular, vesicular, or bullous lesions. The disease is strongly associated with the presence of HLA-B8 and HLA-DR3 antigens. A variety of different autoantibodies has been detected in small numbers in patients with dermatitis herpetiformis.	0	3.03	1	0
Atherogenesis [description not available]	0	2.77	3	0
Alloxan Diabetes [description not available]	0	2.11	1	0
Diabetic Glomerulosclerosis [description not available]	0	2.49	2	0
Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.	0	2.49	2	0
Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.	0	2.77	3	0
Carcinoma, Small Cell Lung [description not available]	0	2.13	1	0
Small Cell Lung Carcinoma A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).	0	2.13	1	0
Sarcoma, Epithelioid [description not available]	0	2.11	1	0
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	0	2.11	1	0
Myxoid Liposarcoma [description not available]	0	2.13	1	0
Liposarcoma, Myxoid A liposarcoma containing round mesenchymal cells and a myxoid extracellular matrix in stroma.	0	2.13	1	0
Recrudescence [description not available]	0	3.93	2	1
B-Cell Chronic Lymphocytic Leukemia [description not available]	0	5.11	5	2
Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.	0	5.11	5	2
Hypertrophy General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).	0	2.13	1	0
Diabetes Mellitus, Adult-Onset [description not available]	0	2.13	1	0
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	0	2.13	1	0
MODS [description not available]	0	2.13	1	0
Multiple Organ Failure A progressive condition usually characterized by combined failure of several organs such as the lungs, liver, kidney, along with some clotting mechanisms, usually postinjury or postoperative.	0	2.13	1	0
Endotoxemia A condition characterized by the presence of ENDOTOXINS in the blood. On lysis, the outer cell wall of gram-negative bacteria enters the systemic circulation and initiates a pathophysiologic cascade of pro-inflammatory mediators.	0	2.13	1	0
Heatstroke [description not available]	0	2.13	1	0
Heat Stroke A condition caused by the failure of body to dissipate heat in an excessively hot environment or during PHYSICAL EXERTION in a hot environment. Contrast to HEAT EXHAUSTION, the body temperature in heat stroke patient is dangerously high with red, hot skin accompanied by DELUSIONS; CONVULSIONS; or COMA. It can be a life-threatening emergency and is most common in infants and the elderly.	0	2.13	1	0
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	0	2.13	1	0
Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES.	0	2.13	1	0
Adenocarcinoma, Basal Cell [description not available]	0	3.01	4	0
Cancer of Pancreas [description not available]	0	3.3	6	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	0	3.01	4	0
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	0	3.3	6	0
Cryptogenic Fibrosing Alveolitis [description not available]	0	2.15	1	0
Idiopathic Pulmonary Fibrosis A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.	0	2.15	1	0
Cancer of Kidney [description not available]	0	2.04	1	0
Injury, Ischemia-Reperfusion [description not available]	0	2.44	2	0
Kidney Neoplasms Tumors or cancers of the KIDNEY.	0	2.04	1	0
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	0	2.44	2	0
Adult Spinal Muscular Atrophy [description not available]	0	2.05	1	0
Muscular Atrophy, Spinal A group of disorders marked by progressive degeneration of motor neurons in the spinal cord resulting in weakness and muscular atrophy, usually without evidence of injury to the corticospinal tracts. Diseases in this category include Werdnig-Hoffmann disease and later onset SPINAL MUSCULAR ATROPHIES OF CHILDHOOD, most of which are hereditary. (Adams et al., Principles of Neurology, 6th ed, p1089)	0	2.05	1	0
Diffuse Lymphocytic Lymphoma, Poorly-Differentiated [description not available]	0	2.05	1	0
Lymphoma, Mantle-Cell A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).	0	2.05	1	0
Carcinoma, Epidermoid [description not available]	0	2.05	1	0
Cancer of Cervix [description not available]	0	2.45	2	0
Metastase [description not available]	0	2.05	1	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	0	2.05	1	0
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	0	2.45	2	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	0	2.05	1	0
ATLL [description not available]	0	2.05	1	0
Leukemia-Lymphoma, Adult T-Cell Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.	0	2.05	1	0
Graft-Versus-Host Disease [description not available]	0	2.05	1	0
Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.	0	2.05	1	0
Constriction, Pathological [description not available]	0	2.05	1	0
Peripheral Nerve Diseases [description not available]	0	2.05	1	0
Constriction, Pathologic The condition of an anatomical structure's being constricted beyond normal dimensions.	0	2.05	1	0
Peripheral Nervous System Diseases Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.	0	2.05	1	0
Arachnoidal Cerebellar Sarcoma, Circumscribed [description not available]	0	2.05	1	0
Experimental Neoplasms [description not available]	0	3.15	5	0
Medulloblastoma A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)	0	2.05	1	0
Blast Phase [description not available]	0	3.44	1	1
Granulocytic Leukemia, Chronic [description not available]	0	3.44	1	1
Blast Crisis An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.	0	3.44	1	1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	0	3.44	1	1
Duncan Disease [description not available]	0	2.05	1	0
Lymphoproliferative Disorders Disorders characterized by proliferation of lymphoid tissue, general or unspecified.	0	2.05	1	0
Kahler Disease [description not available]	0	4.06	5	0
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	0	4.06	5	0
Peritoneal Carcinomatosis [description not available]	0	2.05	1	0
Peritoneal Neoplasms Tumors or cancer of the PERITONEUM.	0	2.05	1	0
Rotavirus Infections Infection with any of the rotaviruses. Specific infections include human infantile diarrhea, neonatal calf diarrhea, and epidemic diarrhea of infant mice.	0	2.06	1	0
Nasopharyngeal Carcinoma A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.	0	2.07	1	0
Carcinoma, Anaplastic [description not available]	0	2.07	1	0
Cancer of Nasopharynx [description not available]	0	2.07	1	0
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	0	2.07	1	0
Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX.	0	2.07	1	0
Chondrodystrophic Myotonia [description not available]	0	2.47	2	0
Rachitis [description not available]	0	2.06	1	0
Liver Dysfunction [description not available]	0	2.07	1	0
Liver Diseases Pathological processes of the LIVER.	0	2.07	1	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	0	2.45	2	0
Multiple Endocrine Neoplasia Type 1 A form of multiple endocrine neoplasia that is characterized by the combined occurrence of tumors in the PARATHYROID GLANDS, the PITUITARY GLAND, and the PANCREATIC ISLETS. The resulting clinical signs include HYPERPARATHYROIDISM; HYPERCALCEMIA; HYPERPROLACTINEMIA; CUSHING DISEASE; GASTRINOMA; and ZOLLINGER-ELLISON SYNDROME. This disease is due to loss-of-function of the MEN1 gene, a tumor suppressor gene (GENES, TUMOR SUPPRESSOR) on CHROMOSOME 11 (Locus: 11q13).	0	2.07	1	0
Kidney Failure A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.	0	2.07	1	0
Renal Insufficiency Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.	0	2.07	1	0
Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.	0	2.07	1	0
Libman-Sacks Disease [description not available]	0	2.07	1	0
Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.	0	2.07	1	0
Rhabdomyosarcoma A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)	0	2.07	1	0
Poultry Diseases Diseases of birds which are raised as a source of meat or eggs for human consumption and are usually found in barnyards, hatcheries, etc. The concept is differentiated from BIRD DISEASES which is for diseases of birds not considered poultry and usually found in zoos, parks, and the wild.	0	2.07	1	0
Glial Cell Tumors [description not available]	0	2.02	1	0
Cancer of Prostate [description not available]	0	3.63	3	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	0	2.02	1	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	0	3.63	3	0
Female Genital Neoplasms [description not available]	0	2.02	1	0
Genital Neoplasms, Female Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).	0	2.02	1	0
Germinoblastoma [description not available]	0	3.82	2	1
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	0	8.82	2	1
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted [description not available]	0	2.03	1	0
Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.	0	2.03	1	0
Cancer of Stomach [description not available]	0	2.03	1	0
Stomach Neoplasms Tumors or cancer of the STOMACH.	0	2.03	1	0
Uveal Neoplasms Tumors or cancer of the UVEA.	0	2.04	1	0

17-(dimethylaminoethylamino)-17-demethoxygeldanamycin

Description

Cross-References

Synonyms (45)

Research Excerpts

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (5)

Protein Targets (27)

Inhibition Measurements

Activation Measurements

Biological Processes (192)

Molecular Functions (84)

Ceullar Components (47)

Bioassays (120)

Research

Studies (254)

Market Indicators

Research Demand Index: 14.32

Study Types

17-(dimethylaminoethylamino)-17-demethoxygeldanamycin

Description

Cross-References

Synonyms (45)

Research Excerpts

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (5)

Protein Targets (27)

Inhibition Measurements

Activation Measurements

Biological Processes (192)

Molecular Functions (84)

Ceullar Components (47)

Bioassays (120)

Research

Studies (254)

Market Indicators

Research Demand Index: 14.32

Study Types

Related Drugs (148)

Related Conditions (227)